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Development of novel methods to minimize the impact of sequencing errors in the 
next-generation sequencing data analysis 
Publication No._____________ 
Xiaofeng Zheng, M.S. 
Supervisory Professor: Shoudan Liang, Ph.D 
 
  
 Next-generation sequencing (NGS) technology has become a prominent tool in 
biological and biomedical research. However, NGS data analysis, such as de novo 
assembly, mapping and variants detection is far from maturity, and the high sequencing 
error-rate is one of the major problems. .  
To minimize the impact of sequencing errors, we developed a highly robust and 
efficient method, MTM, to correct the errors in NGS reads. We demonstrated the 
effectiveness of MTM on both single-cell data with highly non-uniform coverage and 
normal data with uniformly high coverage, reflecting that MTM’s performance does not 
rely on the coverage of the sequencing reads. MTM was also compared with Hammer 
and Quake, the best methods for correcting non-uniform and uniform data respectively. 
For non-uniform data, MTM outperformed both Hammer and Quake. For uniform data, 
MTM showed better performance than Quake and comparable results to Hammer. By 
making better error correction with MTM, the quality of downstream analysis, such as 
mapping and SNP detection, was improved. 
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 SNP calling is a major application of NGS technologies. However, the existence 
of sequencing errors complicates this process, especially for the low coverage (<5×) 
data. Since many NGS studies are now based on data with low to medium coverage 
(<20×), on which most existing SNP calling methods perform poorly, we developed a 
Bayesian-based approach for calling SNPs  that is robust to the sequencing depth. We 
successfully applied this approach to identify the SNPs in prostate cancer cell line PC-3 
and colon cancer cell lines RKO and SW48, whose mutation status are unknown. Our 
method outperforms the existing methods - Varscan and DNAnexus - by identifying 
more SNPs while maintaining higher dbSNP rates, especially for the low coverage PC-3 
data. In summary, we identified 107 potential causal genes for PC-3. For RKO and 
SW48 cell lines, 701 and 652 potential causal genes were identified respectively, and 
297 genes are in common. With the ability of piggybacking on the ChIP-Seq, RNA-Seq 
and other data with low or uneven coverage, this approach is expected to have a wide 
range of applications. 
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 Next-generation sequencing (NGS), as one of the most influential breakthroughs 
in the biological sciences in the past decades, revolutionized the genomic research. The 
introduction of NGS technology has changed the way to acquire genetic information 
from various species to an unprecedented level on speed and cost.  
1. Advance in DNA sequencing technologies 
 DNA sequencing is the process to examine the nucleotide order of a DNA 
sequence. Deciphering DNA sequence plays an essential role in biological researches. 
Since early 1990s, the capillary electrophoresis (CE) - base Sanger sequencing [1-3] has 
dominated the industry of genome analysis for almost two decades and led to many 
monumental accomplishments, including finishing a "rough draft" of human genome [4]. 
However, Sanger sequencing is hampered by its inherent limitation on throughput, 
scalability and speed. Thus, an entirely new technology is required to overcome such 
limitations.  Sanger sequencing was considered as the first-generation sequencing, and 
the new sequencing technologies are referred as next-generation sequencing. It has been 
seven years since the advent of NGS, and the increase of its data output has outpaced 
Moore's law, at a rate of more than doubling each year. In 2007, a single sequencing run 
produced the maximal 1 GB data, and in 2011, 1TB data could be produced in a single 
sequencing run, which is ~1000 times of increase.  Meanwhile, the dropping speed of 
the sequencing cost is faster than Moore’s law. These days, more than five human 
genomes can be sequenced in a single run with the cost of less than $5,000, and analyze 
the data within one week. In comparison, the Sanger sequencing would take ~10 years 
to produce these data and additional 3 years to finish the analysis, which costs nearly 3 
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billion US dollars. Figure 1.1 shows the cost change of sequencing a human-sized 
genome. 
 
2. Platforms of NGS 
 NGS is the technology that can sequence millions of DNA sequences in parallel. 
It includes two types of techniques, which are distinguished with the names of "second-
generation" and "third-generation".  Second-generation sequencing works by 
amplifying the DNA templates immobilized on a solid matrix and sequencing them 
cyclically, while the third-generation sequencing employ single molecule PCR-free and 
cycle-free protocols. There are three second-generation platforms: 454 sequencing 
(Roche Applied Science), Solexa sequencing (Illumina Genome Analyzer), and SOLiD 
sequencing (Applied Biosystems). The third-generation sequencing such as Pacific 
Biosciences  is still not mature and may take may take a few years to rival the second-
generation platforms and become the mainstream of the market. Therefore, we will only 
discuss the second-generation platforms here. The comparison of these three second-
generation sequencing platforms is in Table 1.1. 
 
2.1. Roche 454 system 
 Roche 454 technology is the first NGS technology that was released to the 
market in 2005. Initially in 2005, the read length of 454 was 100-150 bp, and the output 
per run is 20Mb. In 2008, the upgraded 454 GS FLX system was able to produce 700bp 
long reads, the accuracy of which is 99.9% after filtering. On average, 0.7 G data was 
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Figure 1.1 Typical cost of sequencing a human-sized genome, on a logarithmic 
scale. Note that the drastic trend faster than Moore's law beginning in January 2008 as 
NGS was invented [6]. 
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Table 1.1. Comparison of sequencing platforms [7]. (a) Advantage and mechanism of 
sequencers. (b) Components and cost of sequencers. (c) Application of sequencers. 
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output per run within 24 hours. In late 2009, the output of 454 system had upgraded to 
14G per run. The advantages of 454 were its longer read length and faster speed (10 
hours from starting to completion). However, the high cost of reagents (about $12.56 
per million bases) became a big shortcoming of 454 system. Also, for the poly-bases 
longer than 6bp, the error rate was relatively high. The comparison of 454 with HiSeq 
from Illumina and SOLiD are in Table 1.1. 
 
2.2. Illumina GA/HiSeq system 
 Genome Analyzer (GA) was released by Solexa in 2006, and then purchased by 
Illumina company in 2007. At first, the output of Solexa GA was 1G/run, and then 
increased to 20G/run in August, 2009, and 30G/run and 50G/run respectively in 
October and December in the same year. The latest release, GAIIx series, can have 
85G/run. In 2010, Illumina adopted the same sequencing strategy with GA to get HiSeq 
2000 launched. The output of HiSeq 2000 was 200G/run initially and improved to 
600G/run recently and finished in 8 days. In the short run, it is expected to reach 1T/run, 
and the cost of sequencing a personal genome would drop below 1K US dollars. The 
average error rate could be below 2% after filtering. As the cheapest platform, HiSeq 
2000 is able to sequence one million bases with only$0.02. 
  
2.3. AB SOLiD system 
 In 2006, after the Solexa was released, SOLiD (Sequencing by Oligo Ligation 
Detection) entered the market in 2007. Initially, the read length of SOLiD produced 3G 
35-bp-long reads per run. By means of the dinucleotide sequencing method, the 
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accuracy of SOLiD could reach 99.85% after filtering. In late 2010, three years later, 
with the release of SOLiD 5500xl sequencing system,30G reads with of the length of 85 
bp and accuracy of 99.99% were produced in a single run in 7 days. The current cost 
using SOLiD 5500xl  is about $0.04/million bases. But the limitation on de novo 
sequencing and large genome sequencing is still its major shortcoming. 
3. Mechanism for various platforms of NGS 
 Although the sequencing biochemistry and the array generation are quite diverse 
for different platforms, their workflows are similar in concept (Figure 1.2). Second-
generation sequencing follows two principles: DNA templates immobilized and 
separated on a solid matrix are amplified with DNA polymerase; the replicated DNA 
are sequenced cyclically. For the library preparation, the DNA sequences are randomly 
fragmented and ligated to common adaptor sequences in vitro. PCR primers 
complementary to the adaptor sequences are used to amplify the library immobilized on 
the support matrix for amplification purpose. Emulsion PCR (emPCR) was employed 
by both SOLiD and Roche 454 system to clone DNA templates linked to beads [8]. The 
concentration of beads and template that are added to a water and oil emulsion are 
controlled carefully to guarantee each emulsion droplet only contains one bead and one 
DNA template. We call the amplified beads sequencing features. After emPCR, the 
sequencing features are randomly deposited to pico-wells [11, 12]. Differently from 454 
and SOLiD, Solexa employs bridge PCR to generate clonally amplified DNA clusters 
[13].  
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Figure 1.2. Work flow of second-generation sequencing. In shotgun sequencing with 
cyclic-array methods, common adaptors are ligated to fragmented genomic DNA, which 
is then subjected to one of several protocols that results in an array of millions of 
spatially immobilized PCR colonies or "polonies" [9]. Each polony consists of many 
copies of a single shotgun library fragment. As all polonies are tethered to a planar array, 
a single microliter-scale reagent volume (e.g., for primer hybridization and then for 
enzymatic extension reactions) can be applied to manipulate all array features in parallel. 
Similarly, imaging-based detection of fluorescent labels incorporated with each 
extension can be used to acquire sequencing data on all features in parallel. Successive 
iterations of enzymatic interrogation and imaging are used to build up a contiguous 
sequencing read for each array feature [10].  
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 Each NGS platform uses a unique sequencing chemistries and methods for 
signal detection. 454 employs pyrosequencing, whereby the nucleotide species is 
indicated by the chemiluminescent and the number of bases incorporated are correlated 
to the intensity of signal. Illumina uses reversible dye terminator in each cycle to 
incorporate a single base, and then image and cleave the terminator in the end. Solid 
employs sequencing by ligation to measure every base twice by dinucleotide encoding.  
 Compared with Sanger sequencing, NGS has the following advantages: (1) 
construction of a sequence library and clonal amplification all in vitro provide the basis 
of parallel sequencing, which breaks the limitation of conventional sequencing. (2) The 
replacement of the conventional capillary-based sequencing with array-base sequencing 
greatly increases the degree of parallelism. As the size the array features are in the scale 
of micrometer, the imaging process becomes more efficient. (3) The array-based design 
dramatically reduced the dosage of reagent from the scale of microliters to picoliters or 
femtoliters per feature drop. All these advantages result in the remarkably lower cost of 
NGS. 
 
4. Applications of NGS 
4.1. Whole genome sequencing 
 Whole genome sequencing is the sequencing process that determines the 
complete DNA sequence of organism's genome at a single time. It includes de novo 
sequencing and whole genome resequencing. De novo sequencing is the sequencing 
without prior knowledge of the sequenced genome, and its purpose is to assembly a new 
10 
 
genome with the sequencing reads. De novo sequencing is required for decipher the 
unknown genomes. As a predominant application of NGS, whole genome resequencing 
can provide complete genetic information for individual's genome or cancer genome. It 
is usually used to detect genome-wide single nucleotide variants, indels, copy number 
variations, and genomic rearrangements [14]. 
 
4.2. Targeted Sequencing 
 Targeted sequencing is the process that only sequence the region that the 
researchers are interested in. Instead of sequencing the whole genome, this method 
reduces the time, cost, and providing a higher sequencing coverage. It is usually used to 
discover the genetic variations by sequencing many individuals. The ability of obtaining 
high coverage enables NGS to identify rare variants. 
 Amplicon sequencing is one of the targeted sequencing techniques that 
sequences selected genome regions of hundreds of base pairs long. Amplicon library 
can be prepared with commercially available kits, which allow the researchers to 
prepare the customized targeted region from multiple samples within hours. 
 Similarly to Amplicon sequencing, target enrichment is also a technique that 
selectively sequences the genes or regions that researchers are interested in. Differently 
to Amplicon, target enrichment allows researchers to sequence longer DNA sequences 
and larger amount of DNA from each sample. A lot of kits are available for the 
researcher to prepare the library. People can also design their own probes to sequences 
the regions related to their interest. Exome sequencing, also known as exome capture, is 
the most popular application of target enrichment approaches. It only sequence the 
11 
 
protein coding regions of the genome. Compared to whole genome sequencing, it is 
cheaper, but still effective. Exons constitute about only 1% of the human genome [15], 
which is ~30Mb in length, but about 85% of the disease-causing mutations are 
associated with these regions [16]. The work flow of exome capture is shown in Figure 
1.3. 
 
4.3. RNA-Seq 
 RNA-Seq, also known as  an "Whole Transcriptome Sequencing" [17], is an 
approach that sequences cDNA with NGS technologies to obtain information about the 
RNA content of a sample. It has been adopted to the disease associated studies and 
dubbed "a revolutionary tool for transcriptomics" [18]. With the deep coverage and 
base-level resolution, RNA-Seq is primarily used to study the gene expression profiling, 
including gene alleles and differently spliced transcripts [19]. Meanwhile, RNA-Seq is 
often used to provide information about non-coding RNAs, post-transcriptional variants, 
and gene fusions. However, the significantly different expression levels between genes 
usually result in insufficient coverage to accurately call variants. 
 The RNA library preparation varies for different platforms of NGS [18], each of 
which has several kits designed to build different types of libraries. However, the 
workflows of different sequencing technologies are similar in concept. To separate the  
coding RNA from non-coding RNA, poly(T) oligos are designed to covalently attached 
to the 3' poly(A) tail of mRNA. Magnetic beads are used in many studies for this step 
[17, 21]. The next step is to reversely transcribe the RNA to cDNA and further fragment  
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Figure 1.3 Exome sequencing workflow . 
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the cDNA to reach the desired length. The templates are then ready to be prepared for 
the sequencing. The workflow of RNA-Seq is shown in Figure 1.4. 
 
4.4. ChIP-Seq 
 ChIP-Seq (chromatin immunoprecipitation sequencing) is used to identify the 
binding sites of DNA-associated proteins. ChIP-Seq is primarily used to study how 
DNA-associated proteins, such as transcription factors and histone, interact with DNA 
to regulate the gene expression, which plays an essential role in deciphering biological 
processes.  
 Some DNA sites interact directly with transcription factors or other proteins to 
form DNA-protein complexes, which can be isolated by chromatin immunoprecipitation 
with antibody against the protein of interest. Then the small pieces of DNA bound to the 
interested protein are ligated to oligonucleotide adaptors for the following sequencing 
(Figure 1.5).  
 
5. Bioinformatics for NGS 
 Although the NGS technologies are developing at a rapid pace, the short read 
and the sheer scale data remains a significant challenge in data analysis. 
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Figure 1.4 Workflow of RNA-Seq . 
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Figure 1.5 Workflow of RNA-Seq .  
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5.1. Sequencing error and quality score 
 The primary data from NGS consists of raw sequencing reads and the quality 
score for each base. The quality scores from different sequencing platforms cannot be 
compared directly, but all of them are Phred-like scores that are related to the 
sequencing error probabilities logarithmically. Different sequencing platforms generate 
various types of error. For the 454 platform, the length of each homopolymer is inferred 
from the observed fluorescence intensity, while the variance of the intensity for a 
specific homopolymer length is large. So 454 system has high error rate in insertion and 
deletion (indel) calls. For the Illumina platform, indels are rare. The major sequencing 
errors come from miscall, with a typical rate of ~1%. The SOLiD platform uses 
dinucleotide encoding scheme, in which each base is called twice. Thus the sequencing 
error rate in SOLiD is relatively smaller. For both Illumina and SOLiD platforms, base 
calling becomes less accurate towards the ends of reads. Depending on the platform, the 
error rate of NGS data ranges from several per cent to tenths of per cent. Reducing the 
sequencing errors is important to the assembly, alignment, variants detection and other 
downstream genomic analysis. 
5.2. NGS analysis pipeline 
 Usually after the NGS reads are generated, the first step is either aligning the 
reads to a reference genome or doing de novo assemble, which is the basis of the 
analysis thereafter. 
17 
 
5.2.1. Alignment 
 Aligning the massive, short sequencing reads to the huge reference genome is a 
computationally complicated problem. Many alignment algorithms were developed and 
some the most popular ones are MAQ, BWA and bowtie. Illumina has developed their 
own aligner Eland, and SOLiD also developed Bioscope for their customers. There are 
some limitations to the alignment approaches. Errors often occur because of the 
ambiguous bases and the sequencing errors in the short reads. Multi-mapping are 
frequently observed when the reads are placed in the repetitive regions in the reference 
genome [24]. Moreover, the presence of gaps and misassemblies in the imperfect 
reference genome also leads to misalignment [25, 26]. Pair-end reads can resolve the 
misalignment for some repetitive regions if one read in the pair is unique to the genome. 
 
5.2.2. De novo assembly 
 de novo assembly refers to aligning and merging the sequencing reads to 
reconstruct the original sequenced genome. It is important as the reference genome is 
lack for most species. Compared with alignment, assembly is computationally orders of 
magnitude slower and more memory intensive. De novo assembly has been successfully 
applied to assemble the bacterial genomes and mammalian bacterial artificial 
chromosomes [27-31]. However, the application to human genome remains a 
substantial challenge. The short read length usually leads to a lot of gaps, regions 
without reads aligned, and the sequencing errors often cause branching, resulting in 
poor assembly quality. Pair-end reads could partially resolve this problem and produce 
longer contigs by filling gaps in the consensus sequence. 
18 
 
 
5.2.3. Variants detection 
 Variants detection is one of the most important applications of NGS, with the 
challenge of separating the real variants from sequencing errors. Most variants detection 
methods use Bayesian algorithms to estimate the probability of calling a variant at a 
specific position. Variants detection has become more sophisticated and the further 
steps, such as local realignment around indels, quality score recalibration, and removal 
of duplicates, are usually implemented to improve the accuracy of variant calling. Once 
the variants are detected, they are typically annotated to predict the functional 
significance.  
 
6. Significance and specific aims 
 Since the first introduction in 2005, NGS technologies have generated an 
incredible impact on genomic research. They have been broadly applied to many fields 
including genomic variation detection, gene expression and profiling, protein-DNA 
interaction, detection of aberrant transcription, small ncRNA discovery and profiling, 
genome annotation, and epigenomics. However, the development of methods for NGS 
data analysis is far away behind the advances of NGS technology itself. More efficient 
data analysis methods are required to establish pipeline for many applications before the 
analysis becomes routine. One major obstacle of data analysis is sequencing error, 
which affects the efficiency and accuracy of the analyzed results. Therefore, the purpose 
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of my study is to design data analysis methods that can minimize the effect from 
sequencing errors. The two aims are described as below: 
1) To design a robust and efficient error-correction method to correct the 
sequencing reads before the downstream analysis. Most of the existing error-
correction methods require high and uniform coverage, which does not fit some 
sequencing applications, such as single-cell sequencing, and mRNA-Seq. Here, 
we will design an error-correction method without any requirement for the 
sequencing coverage.  
2) To design a SNP calling method. The existence of sequencing error usually 
results in low SNP-calling accuracy for low coverage data. Here we will design 
a new model to accurately detect the SNPs without requirement for the 
sequencing depth of the data. 
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CHAPTER TWO 
 
MTM: An Error-Correction Method for High-
Throughput Sequencing Data 
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1. SUMMARY 
Background 
 NGS technologies produce massive amounts of short reads. The high 
sequencing error rate has become one of the major obstacles in sequencing data 
applications, such as de novo assembly and re-sequencing. Thus, error correction prior 
to data analysis is a critical step for the success of downstream analysis. Several error-
correction methods have been developed in recent years. Most of those methods work 
with the assumption that sequencing reads are uniformly distributed. Although a few 
methods work well on the non-uniform data, they are computationally expensive and do 
not perform as well as the uniformity-specific methods on the uniform data. Therefore, 
a robust and efficient error-correction method is in urgent need.  
Results 
 We report MTM, a new method for correcting errors in the NGS reads without 
the uniformity assumption. By using a mutating-testing algorithm, MTM outperforms 
the pervious error-correction methods with robustness, as well as higher positive 
predictive values and sensitivities. We also demonstrated the improvements of error 
correction with MTM on the mapping and variant detection. 
Conclusions 
 MTM is a robust and efficient error correction method for NGS data, which can 
improve the quality of the results in the subsequent analysis. It is implemented in C++ 
and has been released as a software package downloadable at 
https://sites.google.com/site/mtmerrorcorrection/ 
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2. INTRODUCTION 
    NGS technology developed in the last decade provides monumental increase in 
speed and volume, taking biological and biomedical research to a whole new level. For 
example, tumour samples from thousands of patients (TCGA) have been sequenced in 
order to discover the complete set of oncogenes and tumour suppressor genes. The 1000 
Genome Project is using sequencing to establish by far the most detailed catalogue 
of human genetic variations [32]. Thus far, the applications are mostly confined to the 
organisms whose genomes have been sequenced. A more exciting possibility is to 
expand the new sequencing capacity to the study of genome biology of previously 
unexplored organisms. Meanwhile, the Genome 10K Project plans to sequence and 
assemble the genomes of 10,000 vertebrate species [33].  
 Compared to the traditional shotgun methods [34], the NGS techniques generate 
a much larger set of shorter reads with higher error rates, which challenge the 
downstream analysis tools. Sanger reads, typically 700-1000 bp long, were assembled 
using an overlap-layout-consensus approach, which would be too slow when applied to 
the NGS data. Thus, a new method has been developed using de Bruijn graph [35] that 
is much faster to compute large amount of sequencing data [36]. However, methods 
based on de Bruijn graph are highly sensitive to sequencing errors [37], which cause 
branching in the graph and greatly increase the computational cost. Therefore correcting 
sequencing errors before assembly is a build-in feature of almost all de Bruijn 
assemblers. Re-sequencing is another important application of NGS technology. Reads 
are aligned to the reference genome by allowing up to a fixed number of mismatches 
caused by either polymorphisms or sequencing errors [38]. Therefore, some reads are 
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difficult to be mapped to the reference genome due to the sequencing errors, especially 
in the polymorphism-rich regions. Pre-processing the reads to eliminate sequencing 
errors will improve the mapping ability. Subsequently, the sensitivity and specificity of 
variant detection will be improved as well. 
 The general idea behind error correction methods is to align all the reads that 
cover the same genome locations, and identify the erroneous base using the high 
coverage of the NGS technology. As the reference genome is unknown, the reads from 
the same genome location refer to the reads sharing the same subsequence of a fixed 
length k, called k-mers [39]. Established error correction methods can be classified into 
three types - k-spectrum based [28, 36, 40-47], suffix tree/array-based [48-50] and 
multiple sequence alignment (MSA) -based methods [51, 52]. A common approach of 
error correction is to use the frequency of k-mers to separate them into trusted k-mers 
and untrusted k-mers. k-mers with low frequency usually represent sequencing errors, 
while k-mers with high frequency are likely to occur in the genome. When the 
sequencing coverage is high and uniform, the distributions of trusted k-mers and 
untrusted k-mers are separated. By choosing a right threshold, they can be separated 
very well [28, 36, 43, 46, 47]. However, these methods do not work well when the data 
does not cover the genome uniformly. For example, data from transcriptome sequencing 
(RNA-Seq) and single-cell sequencing, the coverage of which are dramatically uneven. 
Also, when the DNA is from environmental samples and cannot be cloned, the amount 
of starting materials is small. Using above methods to pre-process these data is not 
effective and results in loss of real reads. Another popular approach is based on 
Hamming graph. k-mers within a small Hamming distance are grouped together, and the 
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k-mers with low frequency are corrected to the high-frequency k-mer [44, 48-50, 53, 54]. 
Although some of these methods work well for non-uniform data, but they can be 
computationally expensive and do not perform as well as the methods based on k-mers 
frequency on uniform data.  
 In this paper, we present a new method MTM to correct sequencing errors, 
without the assumption on the uniformity of the data. MTM is similar in spirit to the 
Hammer graph methods. It assumes that the k-mer population is consisted of high 
frequency error-free k-mers and low frequency erroneous k-mers, and that an erroneous 
k-mers can be linked to an error-free k-mer by a small number of point mutations. It 
further assumes that the ratio of the frequencies of the linked k-mers is consistent to the 
sequencing error rate. MTM outperforms the previous non-assumption methods on both 
uniform and non-uniform data, and achieved similar performance to uniformity-specific 
methods on uniform data. MTM is efficient on dealing with large datasets or data with 
high error rates without the limitation on memory. Moreover, MTM allows users to 
choose a large range of k-mer length, providing more flexibility for the downstream 
analysis. Finally, we explored the impact of error correction with MTM on mapping 
ability and variant detection. After error correction, we were able to map more reads to 
the reference genome, and identify more variants while remaining the same precision. 
3. MATIRIALS & METHODS 
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3.1. Data 
 To test the effectiveness of MTM on both uniform and non-uniform datasets, we 
used two data sets: 1) Single-cell data with highly non-uniform coverage [55]. The 
reads were amplified from a single-cell of E.coli K12 MG1655 and sequenced by the 
Illumina GAII pipeline (lane 1). The 100 bp long reads with ~600× sequencing depth 
result in 94 blackout regions and totally 116 kbp with 0 or 1 coverage. 2) Normal multi-
cell data with uniform coverage (ERX002508). The data were also generated from 
E.coli K-12 MG1655 and sequenced by the Illumina GAII pipeline with the same 
coverage and read length. 
 Since the sequencing accuracy is low at the beginning and end of a read, prior to 
working with the datasets, we trimmed the reads by only keeping the longest region of a 
read that are longer than k (size of oligonucleotide) and do not contain ambiguous bases 
or bases with quality score lower than QUAL_LOW. In this study, we let QUAL_LOW 
equal 3. 
  
3.2. Statistical model 
  Two k-mers S1 and S2 with multiplicities   and   (     ) have one 
nucleotide difference in the sequences. Then S2 may either be sequenced from S1 with 
one sequencing error or be a true repeat of S1 .To distinguish the sequencing error from 
repeat, we tested if the percentage of S2 is consistent with the average sequencing error 
rate. Define q as the average sequencing error rate and p as the percentage of k-mer S2. 
Then  
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The distribution of D is close to    distribution. By defining a significance level α, null 
hypothesis is rejected if     , where          . The rejection of null 
hypothesis indicates that k-mer S2 is not the erroneous form of S1. 
 
3.3. Algorithm 
 MTM detects and corrects the sequencing errors by converting the reads to k-
mers and distinguishing trusted k-mers from erroneous k-mers, then using the trusted k-
mers to correct the original reads. Because sequencing error is small, the error free 
sequences should occur more frequently than the sequences with errors. Thus, k-mers 
with higher multiplicities are more trustable. MTM mutates each k-mer and searches for 
its close k-mers with lower multiplicities. If a match is found, the above statistical 
model is applied to determine if the matched k-mer is likely to be an erroneous form of 
the original k-mer. MTM consists of the following steps: 
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1) Counting k-mers: the first step of MTM is cutting the trimmed reads to k-mers 
and counting the occurrences of all k-mers. A read with length L produces 
      k-mers.  
2) Sorting k-mers: k-mers are sorted by their multiplicities from high to low. 
3) Mutating and testing: Starting from the k-mer with highest multiplicity, we 
work on all the k-mers in the order sorted in step 2. For each k-mer So, we 
mutate one nucleotide at a time to generate a new k-mer Sm with only one 
substitutional difference to the original k-mer So. A k-mer can be mutated to    
new k-mers as shown in Figure 2.1(a). Then we search each new k-mer Sm in 
the k-mer list with multiplicities lower than So. Once a match is found, the above 
statistical model is applied to test if Sm is the result of erroneous sequencing of 
Sm. If the testing result shows that Sm is erroneous, Sm will be corrected to So at 
the end of this step. Meanwhile, a table is generated to record erroneous k-mers 
and their corresponding corrected k-mers. Since the mutation and correction 
processes are accumulative, correction could happen between two k-mers with 
more than one bases difference, such as the k-mers Sa and Sc in Figure 2.1(b). 
Moreover, although error free k-mers occur more frequently than erroneous k-
mers, high multiplicity does not guarantee that a k-mer is trustable. It is because 
the sequencing coverage are often uneven, which is especially true when 
amplifying from a small amount of starting materials and in RNA-Seq. Even 
when de novo sequencing is performed at optimal condition, the coverage often 
distributes in a wide range. A non-negligible portion of the genome have high 
coverage. Therefore, a high multiplicity k-mer can be the result of sequencing 
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error from a k-mer with even higher multiplicity, just like Sb in Figure 2.1(b), 
which is erroneous form of Sa. 
4) Correcting sequencing reads: Using the correct k-mers list and the correction 
table mentioned in step 3, we map the correct k-mers back to the original reads. 
If no correct k-mer is mapped to a position, the original base in the read is kept. 
Otherwise, the consensus nucleotide is the base in the final correct sequence of 
the read (Figure 2.2).  
 
3.4. Parameters 
 MTM has three parameters: 1) α, significance level of likelihood ratio test for 
determining if the mutated k-mer is trustable. Setting α too large may reduce the power 
of correction, remaining a lot of erroneous k-mers after correction. Whereas setting α 
too small may reduce the sensitivity, thus losing some true k-mers. We optimized α as 
0.1% in our method (Figure 2.3). 2) k, the length of oligonucleotide MTM works on. 
Like the trades-offs with k-mer size in genome assembly, too small of a k results in a 
high probability that one k-mer in the genome would be similar to another k-mer in the 
genome with only one nucleotide substitution, making the situation more complicated. 
Too large of a k results in low k-mer coverage and reduces the accuracy of algorithm. 
We designed two versions of codes for MTM – binary version and string version. 
Binary version is faster than the string version, while it has a limitation for k (    ). 
3) mulcutoff, the threshold of multiplicity below which the k-mers will be removed. 
Varying the value of mulcutoff results in a trade-off between sensitivity and specificity. 
 
29 
 
 
Figure 2.1. Illustration of k-mer mutation and accumulative correction. (a) One k-
mer is mutated to 3k new k-mers with one nucleotide substitution. (b) This is an 
example of accumulative correction. We mutate k-mer Sa by one nucleotide and find a 
match Sb. The statistical test shows Sb is the result of sequencing error from Sa. So Sb is 
corrected to Sa. Similarly, then we do mutation to Sb and find out that Sc can be 
corrected to Sb. Therefore, Sa is the original correct form of Sc.  
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Figure 2.2. Correction of original sequencing reads with trusted k-mers. This is an 
example indicating the way that the sequencing reads are corrected based on the correct 
k-mers. We mapped k-mers back to the original read, and correct the sequence of the 
original read to the consensus of k-mers. The region with no k-mers mapped is saved. 
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Figure 2.3. Sensitivity ~ PPV plots of MTM with different  values. We measured 
the sensitivities and PPVs by choosing different  values.  value is labeled next to the 
curves. When  changes from 0.1% to 0.01%, the sensitivities decrease. So on balance, 
0.1% is the recommended value for . 
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4. RESULTS 
 MTM corrects errors in the sequencing reads. To achieve this goal, MTM 
converts the reads to k-mers and separates the error-free k-mers from the erroneous k-
mers, and then replaces the k-mers from the original reads with error-free k-mers. 
Therefore, finding out the error-free k-mers is the critical step of MTM. To assess 
MTM's ability, following Medvedev et al.[45], we measured the data's sensitivity and 
positive predictive value (PPV) with respect to the reference E.coli genome. Sensitivity 
is measured by the percentage of E.coli genome's k-mers that are present in the dataset. 
PPV is the percentage of data's k-mers that are present in the E.coli genome.  
 To test the performance of MTM on different k values, two different values of k 
(k = 31 and k = 55) were used to run MTM for each dataset. We ran the binary version 
program for k = 31 and ran the string version program for k = 55. To increase the 
quality of the reads, we trimmed the data before running MTM, and about 85% - 91% 
of the data were preserved. The trimming step did not affect the high sensitivities of the 
data, which are 99.98% (k = 55) and 99.99% (k = 31) for the normal data, and 97.04% 
(k = 55) and 97.72% (k = 31) for the single-cell data. Error correction by MTM 
dramatically reduced the percentage of erroneous k-mers, especially when the mulcutoff 
is larger than one (Figure 2.4). 
 
4.1. Comparison to other methods 
 Quake is a program that is superior in detecting as well as correcting sequencing 
errors in the data with high and uniform coverage [43]. Quake works by weighting the 
k-mer multiplicities with quality values and then modelling the histogram of weighted  
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Figure 2.4. Error correction by MTM removed the majority of the erroneous k-
mers. We measured the PPV of normal and single-cell data by varying mulcutoff in the 
MTM. After the error correction by MTM, the percentage of erroneous k-mers 
dramatically decreased, especially when k ≥ 2. The vertical axis is 1-PPV, which is the 
percentage of data's k-mers that are not present in the E.coli genome. Black color 
represents the results before the correction, and the grey color represents the results 
after correction. 
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multiplicities as at mixture of two distributions to choose an appropriate cutoff between 
error-free k-mers and erroneous k-mers. Quake is not able to find the cutoff for the 
single-cell data, so we manually tried different values as the cutoff and compared the 
results with MTM (Figure 2.5). MTM works better than Quake because its curve is 
closer to the top right corner, which indicates higher sensitivity and PPV. Based on the 
plots, we choose 4 as the cutoff for MTM, because by using the cutoff of 4 MTM is able 
to obtain high PPV with a negligible decrease of sensitivity. Accordingly, the cutoff of 
Quake is set to 3. The number of the comparison results is showed in Table 2.1. MTM 
outperformed Quake for single-cell data with both higher PPV and sensitivity, and 
achieve comparable performance for normal data. When the cutoff is set to 4 for the 
normal data, MTM get higher sensitivity and lower PPV than Quake. When the cutoff is 
increased to 9, MTM win out with higher PPV and the same sensitivity. 
 Another method called Hammer was recently developed, which is popular for its 
good performance on correcting non-uniformly distributed data [45]. Based on a 
combination of Hamming graph and a probabilistic model, Hammer identifies the 
clusters for similar k-mers and generates a consensus k-mer as the error-free k-mer for 
each cluster. We also compared MTM with Hammer, and the results showed that MTM 
improved Hammer on both single-cell data and normal data. Figure 2.5 shows that 
MTM gets higher PPV and sensitivities at various cutoff points for single-cell data. The 
number of the comparison results is shown in Table 2.1, in which the singletonCutoff of 
Hammer is set to 3 according to the plots. With k=55, MTM retained ~16K more true k-
mers, while reduced the erroneous k-mers by ~258K for single-cell data. Similar results 
are obtained with k=31. 
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(a) k = 55 
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(b) k = 31 
 
 
Figure 2.5  Sensitivity ~ PPV plots with different error correction tools. 
For single-cell data, we plotted the sensitivity and PPV with different error correction 
tools by varying the cutoff values. MTM performs better than Quake and Hammer 
because its curve is closer to the upper right corner, where the sensitivity and PPV are 
higher. Cutoff values were labelled next to the curves with the same color as the curve. 
For MTM, the cutoff is mulcutoff, k-mers with the multiplicity below which are 
discarded. For Hammer and Quake, the cutoff is weighted multiplicity. "uc" represents 
"uncorrected", which is the value before correction. 
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Table 2.1   Comparison of MTM results with other tools. MTM outperforms 
Hammer for both single-cell data and normal data. MTM also shows better performance 
than Quake for single-cell data, and comparable results for normal data. The cutoff for 
MTM is the value of parameter mulcutoff, k-mers with the multiplicity below which 
were discarded. The cutoff for Hammer is the value of parameter singletonCutoff in 
Hammer, which is the threshold for the weighted multiplicity. For Quake, the cutoff is 
also based on the weighted multiplicity, and it is calculated automatically by the 
program for normal data. 
 
(a) Comparison results with k = 55. 
  distinct k-mers  correct k-mers  PPV (%)  sensitivity(%)  
Single-cell  Before correction 9,602,1803 4,430,156 4.61 97.04 
 MTM (cutoff = 4) 4,638,400 4,268,971 92.04 93.51 
 Hammer (cutoff = 3) 4,896,130 4,252,619 86.86 93.15 
 Quake (cutoff = 3) 4,703,965 4,178,234 88.82 91.52 
normal  Before correction 81,042,139 4,564,457 5.63 99.98 
 MTM (cutoff = 4) 4,801,122 4,563,700 95.05 99.96 
 Hammer (cutoff = 3) 4,857,315 4,562,884 93.94 99.94 
 Quake  4,725,473 4,562,648 96.55 99.94 
 MTM (cutoff = 9) 4,719,529 4,562,509 96.67 99.94 
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(b) Comparison results with k = 31. 
  distinct k-mers  correct k-mers  PPV (%)  sensitivity(%)  
Single-cell  Before correction 90,598,084 4,450,268 4.91 97.72 
 MTM (cutoff = 4) 4,903,206 4,359,514 88.91 95.72 
 Hammer (cutoff = 3) 5,247,985 4,339,490 82.69 95.28 
 Quake (cutoff = 3) 5,792,076 4,360,114 75.28 95.74 
normal  Before correction 81,128,182 4,553,932 5.61 99.99 
 MTM (cutoff = 4) 4,755,026 4,553,849 95.77 99.99 
 Hammer (cutoff = 3) 4,984,462 4,550,950 91.30 99.93 
 Quake 4,599,644 4,553,533 99.00 99.98 
 MTM (cutoff = 19) 4,597,788 4,553,474 99.04 99.98 
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 The superiority of MTM over Quake and Hammer becomes more significant 
when the data quality is low. In the above analysis, we trimmed the data by setting the 
QUAL_LOW to 3, which  grabbed the longest region in a read that is longer than k and 
does not contain ambiguous base or base with quality score lower than QUAL_LOW. In 
this part, we set the QUAL_LOW to 2. In other words, we kept all the low quality bases 
in the dataset.  As a result, about 8% more data was preserved on average. We plotted 
the sensitivities and PPVs from different methods (Figure 2.6). Compared to Figure 
2.5, the distances between the MTM curve and other two curves are larger, indicating 
that the improvement of MTM on Quake and Hammer is more significant. 
 
4.2. Parameters selection 
 Optimizing the parameters could lead to better performance. The first parameter 
is the length of k-mer. Longer k-mers tend to have more sequencing errors and 
consequently reduce the chance that they can be reached from the trusted k-mer within a 
finite number of mutations. As a result, MTM is expected to work better with smaller k. 
Figure 2.7 shows the results of the single-cell data with k = 55 and k = 31 separately. 
The curve for k = 31 is better because it is closer to the top right corner. This figure 
indicated that the algorithm prefers smaller k. However, if the k-mer is too small, there 
is a greater risk for an unrelated k-mer to accidentally match to the genome. Thus, one 
should balance the pros and cons to choose an appropriate k-mer length. 
 α is the significance level of the statistical test that is used to distinguish the 
trusted k-mers from erroneous k-mers. We measured the sensitivity and PPV by varying  
40 
 
 
Figure 2.6  Sensitivity ~ PPV plots with different tools for low quality data (k=55). 
Single-cell data in this figure was trimmed with QUAL_LOW=2.  Namely, the low 
quality bases were not trimmed off, and only ambiguous bases were removed. With the 
correction results, we plotted the PPV-sensitivity curves for MTM, Hammer and Quake. 
Compared to Figure 2, the distances between MTM curve and other two curves are 
much larger, indicating that the improvement of MTM on Hammer and Quake is more 
significant. Cutoff values were labelled next to the curves with the same color as the 
curve. For MTM, the cutoff is mulcutoff, k-mers with the multiplicity below which are 
discarded. For Hammer and Quake, the cutoff is weighted multiplicity. "uc" represents 
"uncorrected", which is the value before correction. 
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α value (Figure 2.3). When the value of  changes from 1% to 0.1%, the PPV increases, 
while the sensitivity only has a slight decrease. However, the sensitivity decreases 
significantly when  changed from 0.1% to 0.01%. So considering the balance of 
sensitivity and PPV, 0.1% is recommended and is used in our analysis. 
 
4.3. Improvement on mapping ability 
 Aligning the sequencing reads to the reference genome is the first step in the 
application of short reads. Mapping the short reads is usually achieved by allowing a 
fixed number of mismatches [38]. In other words, if the number of sequencing errors in 
a read is larger than the fixed number, the read will not be mapped. Thus, by performing 
error correction before mapping, the mapping ability will be improved. We mapped the 
short reads to their sequencing template E.coli K12 before and after the error correction 
with MTM. We used two different modes of Bowtie to do the mapping [56]. Firstly, We 
mapped the reads with Bowtie's default mode (-n mode), which allows no more than 2 
mismatches in the first 28 bases, and the sum of the Phred quality values at all 
mismatched positions no more than 70. Then, we also did the mapping by allowing up 
to 2 mismatches for the whole read using the -v mode of Bowtie. The results are 
showed in Table 2.2(a). In -n mode, about 50-70K additional reads were mapped after 
the error correction with MTM. And about 220-490K additional reads were mapped 
after the error correction with -v mode. The results clearly indicate the benefits of error 
correction on mapping, especially for the -v mode, which allows a few of mismatches in 
the whole read. 
42 
 
 
Figure 2.7  Sensitivity ~ PPV plots of MTM with different k values. We showed the 
sensitivity ~ PPV plots for k=55 and k=31 by varying the value of mulcutoff. 
Apparently, with k=31, MTM works slightly better. The mulcutoff values were labelled 
next to the curves with the same color as the curve. "uc" represents "uncorrected", 
which is the values before correction. 
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Table 2.2   Mapping results comparison. We used Bowtie to map the reads in two 
different modes: -n mode and -v mode. In -n mode, up to 2 mismatches were allowed in 
the first 28 bases, and the sum of Phred quality of all mismatches should not exceed 70. 
In -v mode, only up to 2 mismatches were allowed in the whole reads. 
 
(a) E.coli K12 as the reference genome. 
  n-mode v-mode 
  before after before after 
lane1 (k=55) 24.92M 
(93.33%) 
24.97M 
(93.51%) 
24.56M 
(91.98%) 
24.78M 
(92.81%) 
normal 
(k=55) 
26.72M 
(99.42%) 
26.77M 
(99.61%) 
26.17M 
(97.37%) 
26.55M 
(98.79%) 
lane1 (k=31) 26.64M 
(93.52%) 
26.71M 
(93.76%) 
26.26M 
(92.16%) 
26.59M 
(93.33%) 
normal 
(k=31) 
27.82M 
(99.41%) 
27.89M 
(99.69%) 
27.25M 
(97.37%) 
27.74M 
(99.13%) 
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(b) E.coli 536 as the reference genome 
  n-mode v-mode 
  before after before after 
lane1 (k=55) 13.43M 
(50.31%) 
13.64M 
(51.09%) 
12.27M 
(45.96%) 
12.96M 
(48.52%) 
normal 
(k=55) 
13.63M 
(50.73%) 
14.03M 
(52.21%) 
12.70M 
(47.27%) 
13.65M 
(50.79%) 
lane1 (k=31) 14.66M 
(51.47%) 
14.91M 
(52.35%) 
13.43M 
(47.13%) 
14.20M 
(49.83%) 
normal 
(k=31) 
14.41M 
(51.48%) 
14.87M 
(53.14%) 
13.43M 
(48.01%) 
14.52M 
(51.88%) 
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 In most cases, the genome being sequenced is different from the reference 
genome due to polymorphisms. The coexistence of SNPs and sequencing errors results 
in difficulties in mapping the reads to the reference genome, especially to the SNP-rich 
regions. So eliminating sequencing errors should benefit more when the reference 
genome is different from the sequenced genome. We used a related genome E.coli 536 
[GenBank: NC_008253] as the reference genome to do the same mapping (Table 2.2 
(b)). About 210-460K additional reads were mapped in -n mode, and about 690-1090K 
additional reads were mapped in -v mode, which demonstrated that error correction by 
MTM improves the mapping ability more significantly when the reference genome is 
different from the sequenced genome. 
 
4.4. Improvement on SNPs calling 
 Variants detection is an important application of NGS. By correcting the 
sequencing errors before identifying the variants, mismatches between the aligned reads 
and reference genome can be reduced. Therefore the SNPs-clustered regions will be 
able to be mapped, resulting in more SNPs to be identified. To explore the benefit of 
error correction with MTM on variants detection, we used the same method that Quake 
used [43]. To call SNPs, we used the data that are sequenced from E.coli K12 but 
aligned to a relative genome E.coli 536 to detect SNPs with SAMtools [57]. To 
calculate the recall and precision statistics of the identified SNPs, we aligned the E.coli 
K12 genome and E.coli 536 genome with the dnadiff utility in MUMmer [58], and used 
the numerated SNPs as the gold standard. The results are showed in Table 2.3. After 
error correction with MTM, we discovered more SNPs. In both -n mode and -v  
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Table 2.3  - SNP calling. We called SNPs using the mapping results from Table 2.2 (b) 
with SAMtools. The SNPs were validated by comparing them with the SNPs from the 
alignment of E.coli K12 genome and E.coli 536 genome. Recall is the fraction of 
identified SNPs in the true SNPs. Precision is the fraction of true SNPs in the identified 
SNPs. 
  SNPs Recall Precision 
  before after before after before after 
k=55 lane1, -n mode 68,270 68,932 0.621 0.627 0.991 0.991 
lane1, -v mode 56,287 56,916 0.512 0.518 0.992 0.992 
normal, -n mode 67,472 68,833 0.615 0.627 0.993 0.993 
normal, -v mode 61,044 61,830 0.556 0.564 0.994 0.993 
k=31 lane1, -n mode 72,622 73,372 0.659 0.666 0.989 0.989 
lane1, -v mode 62,166 63,041 0.565 0.573 0.991 0.991 
normal, -n mode 71,809 73,277 0.653 0.667 0.992 0.992 
normal, -v mode 65,982 67,007 0.601 0.610 0.993 0.993 
 
  
47 
 
mode, the recall increased, while the precision did not change, indicating that the newly 
discovered SNPs are reliable. 
 
5. DISCUSSION  
 The high throughput and low cost of NGS technologies produce a revolution in 
genome research. However, sequencing errors mislead and complicate the analysis of 
sequencing reads. Thus, preprocessing the sequencing reads to eliminate the sequencing 
errors is critical for improving the quality of downstream analysis. Despite the success 
of many error-correction tools, there is a lack of an efficient tool without limitations on 
the reads coverage, k-mer length and memory size. Most error-correction tools rely on 
the uniformity of the reads coverage [39], which is impossible for transcriptome 
sequencing and single-cell sequencing. Hammer is an alternate method working without 
the uniformity assumptions. MTM, the tool we present here, is also an assumption-free 
method. It outperforms the previous methods with higher PPV and sensitivity. 
Especially, when the quality of the data is low, MTM shows more significant 
superiority. 
 There is no limitation on the k-mer length, which is a strength of MTM. We 
found that the processing time and required memory of Hammer increases significantly 
when k is small, making it not applicable in genome assembly. Also, the correction and 
reconstruction steps of Quake do not support large k due to memory limitations (19-
mers require 32 GB). In contrast, the flexibility of  k selection makes MTM easy to 
satisfy various needs. For example, long k-mers have the potential to be used to 
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distinguish the repetitive regions in eukaryotic genomes. We also provide a binary 
option for MTM, which  greatly speeds up the analysis when k is no more than 32.  
 Rather than correcting k-mers, MTM detects putative erroneous k-mers and 
removes them. In other words, using MTM, no new k-mers is introduced and all the k-
mers used to reconstruct the reads come directly from the original reads. As a 
consequence, the error correction by MTM is not able to increase the sensitivity of the 
data. However, without creating new k-mers, MTM eliminates the risk of introducing 
false positive. Error-correction methods are designed to mainly target hyplotype 
genome sequencing so far, including MTM. So extending the current MTM 
implementation on processing highly repetitive eukaryotic genomes is part of our future 
work. This can be achieved by extending the k-mer on both ends and searching their 
consensus k-mers. The surrounding sequencing should have consistent consensus k-
mers with the original k-mer. Furthermore, like most error-correction algorithms, MTM 
only targets on substitution errors, which is the main source of errors in Illumina 
sequencing platform. The emergence of new platforms, such as PacBio sequencer and 
Ion Torrent that are abundant of indels, challenge MTM. So adopting insertions and 
deletions in the error correction process is our next target. 
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CHAPTER THREE 
 
A New Method of Discovering Genome-Wide 
SNPs from Next-Generation Sequencing Data 
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1. SUMMARY 
 
Background 
 The advance of NGS technology provides an unprecedentedly efficient way to 
comprehensively catalogue the human genetic variants. Ideally, SNPs can be effectively 
detected by counting the allele frequency. However, the high sequencing error rates 
complicate the situation, especially for low coverage (< 5×) data. Recently, many NGS 
studies are based on data with low to medium coverage (< 20×). The increasing demand 
for sequencing more samples suggests that the low or medium coverage sequencing 
may be the most common and cost-effective design. Therefore, accurate SNP calling 
methods without the limitation in the sequencing coverage is important to future genetic 
studies. 
Results 
 To improve the existing methods, we developed a Bayesian-based approach for 
calling SNPs without requirement for the sequencing depth. We successfully applied 
this approach to identify the SNPs in prostate cancer cell line PC-3 and colon cancer 
cell lines RKO and SW48, whose mutation status are unknown. Our method 
outperforms the existing methods by identify more SNPs while maintaining higher 
dbSNP rates, especially for the low coverage PC-3 data. Eventually, we identified 107 
potential causal genes for PC-3. For RKO and SW48 cell lines, 701 and 652 potential 
causal genes were identified respectively, and 297 genes are in common. 
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Conclusions 
 The approach we report in this article is highly sensitive and specific. It is not 
only able to accurately detect SNPs from deeply sequenced exome data, it is also able to 
detect SNPs by piggybacking on the ChIP-Seq, RNA-Seq and some other sequencing 
data with low or uneven coverage. We expect our approach to have a wide range of 
applications. 
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2. INTRODUCTION 
 Recent advances of NGS technology reveal limitless insight about the genome, 
transcriptome, and epigenome of any species. The relatively low cost and incredible 
throughput of NGS makes it possible to comprehensively catalogue the genetic 
variation. Projects such as 1000 Genome Project [32] and The Cancer Genome Atlas 
aim to establish a complete search for variations in common diseases.  
 SNP calling refers to the determination of the genome positions where there are 
polymorphisms or at least one of the bases is different from the reference genome. The 
high error rates in NGS often cause considerable uncertainty for the SNP calling results. 
Especially, when the coverage is low (< 5× per site per individual on average), the SNP 
calling is difficult. To reduce the uncertainty of SNP calling, one proven method is to 
sequence the targeted region deeply (> 20× coverage). However, the most common and 
cost-effective sequencing method is to sequence samples in medium (5-20× coverage) 
or low coverage. For example, the 1000 Genome Project sequenced 176 individuals 
genome-widely at about 3× coverage, because this design is more efficient to identify 
rare variants, compared with the design that sequences fewer individuals deeply [59]. 
Therefore, it is crucial to effectively call SNPs in low coverage data, because the 
inferred SNPs will influence downstream analysis. 
 The SNP calling methods can be classified into two types - simple cutoff 
framework and probabilistic framework. In early studies, the SNP calling analysis first 
filter the sequencing data, and only the high-confidence bases would be kept. The most 
common way of filtering the data is to set the threshold of the quality score to Q20. 
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Bases with quality scores smaller than the threshold are ignored. Then the number of 
times that each allele is observed will be counted, and the allele with largest count but 
different from reference genome will be called as SNP. This type of method works well 
when the sequencing depth is high. Some commercially available softwares such as 
Roche's GSMapper, the CLC Genomic Workbech software, and the DNSTAR 
Lasergene software are based on this design. However, for moderate or low coverage 
sequencing data, this method loses valuable information and results  in under-calling. 
Also, this type of method does not provide a measure for the uncertainty of the 
inference. Thus, several probabilistic-based methods were developed [60-65] to solve 
this problem. Briefly, these methods use Bayes' formula to compute the posterior 
probability for each genotype, and the one with highest posterior probability is 
generally called. Then SNP is called based on the genotype calling result. 
 However, most of the existing SNP calling methods do not work well for the 
sequencing data with low or uneven coverage. Here, we propose a simple Bayesian 
approach for detecting SNPs, which is highly sensitive and specific, especially for the 
low coverage sequencing data. We applied our method to a dataset from prostate cancer 
cell line PC-3, which was originally obtained for epigenetic studies of histone 
modifications using ChIP-Seq and thus has low and uneven coverage. Compared with 
Varscan, a popular SNP calling tool that is adaptive to extreme coverage, our method 
called more SNPs with higher quality. We also applied our method to two exome 
sequencing datasets from colon cancer cell lines RKO and SW48 respectively, and it 
shows that our method outperforms both Varscan and DNAnexus - a commercially 
available SNP calling software. The genome-wide mutations of PC-3, RKO and SW48 
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had not been studied previously, so our results will provide valuable information for the 
future cancer study. Also, there are thousands of ChIP-Seq and RNA-Seq experiments 
conducted every year, and our method can piggyback  these data for the SNP analysis. 
We expect our method to have a wide range of application. 
  
3. MATIRIALS & METHODS 
3.1. Data 
  We applied our method to identify the SNPs of three cancer cell lines – prostate 
cancer cell line PC-3, colon cancer cell lines RKO and SW48. PC-3 data was generated 
by Dr. Jean- ierre Issa’s lab and sequenced with Illumina. The data was from 40 lanes 
including input and Chip-seq. The details of the data source are listed in Table S1. 
Totally about 109M reads with length of 30 or 36 passed the purity filter and contained 
no ambiguous nucleotide such as “N”, and they were used to identify the SN s in  C3. 
RKO and SW48 data were from exome capture and RNA-Seq generated by Dr. Marcos 
Estecio. The reads are 75bp long. 64M reads for RKO and 69M reads for SW48 were 
used in our analysis.  
 
3.2. Base-calling error probability calculation 
 Illumina pipeline encodes the quality score from 0 to 62 using ASCII 64 to 126, 
although only 0 - 40 could be expected in the real data. The quality score is in Phred 
55 
 
format, which is related to the base-calling error probability as shown in the following 
equation:  
                                                                
where Q is the quality score and p is the bass-calling error probability. We calculated 
the accuracy of the quality scores using the PhiX data from 8 independent experiments. 
Figure 3.1 shows that the reported quality score is almost identical to the empirical 
quality score. Therefore, in our analysis, we used the reported quality score by Illumina 
to calculate the base-calling error probability. 
 
3.3. Cross-talk matrix generation 
 For a miscalled base, the true nucleotide type is R, the probability of being 
called to nucleotide type S is defined as cross-talk probability     , so      
    |                         , where      {       }, and    . In this article, 
we define the cross-talk matrix as the matrix composed of cross-talk probabilities 
shown as follow:  
 A T G C 
A N/A               
T     N/A          
G          N/A      
C              N/A 
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Figure 3.1 plot of reported quality score versus empirical quality score from the 
PhiX data of 8 independent sequencing experiments. Empirical base-calling error 
probability for a specified reported quality score was calculated by     
  
  
, where    
is the base-calling error probability for reported quality score q,   is the count of 
mismatched bases with reported quality score of q, and    is the total count of bases 
with reported quality score of q. Then the empirical quality score could be obtained 
using Eq. 3.1. 
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So ∑        {      }      . We have proved that the cross-talk matrices for every 
individual lane are consistent in a sequencing run. So we calculate the cross-talk matrix 
for a sequenced sample by using the corresponding PhiX data in the same run. Denote  
     the count of bases miscalled from R to S, we calculated      with the following 
equation: 
     
    
∑        {      }    
                                                
 
3.4. Model for SNP calling 
 A Bayesian algorithm is applied for our  SNP discovery. Basically, for a specific 
genomic position, assuming that we do not know the reference genome, we calculate 
the probability for each nucleotide type based on the data at this position, and the one 
with largest probability is the true nucleotide. If this nucleotide is different from the 
reference genome, we call it a SNP.  For a given genomic position, the aligned bases are 
denoted as D. We divide D into groups based on their nucleotide types. For example, if 
the aligned bases are composed of three types of nucleotide – A, G and C, then D can be 
divided into 3 groups – groups with nucleotide type A, G, or C respectively. Suppose 
there are T groups and the t
th
 group has    bases, then we have   {  }   
  and 
   {   }    
  . Given a nucleotide type   , where    {       }, we use the 
following equation to estimate the probability whether    is the true nucleotide type. 
  (  | )  
  (    )
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  (    )
∑            {      }
               
 
 
  ( |  )       
∑     |            {      }
 
Since the reference genome is assumed to be unknown, we give equal prior probability 
to each nucleotide type, which is                             . Then the 
above equation is simplified to  
  (  | )  
  ( |  )
∑     |      {      }
                                            
To estimate   ( |  ) in Eq. 3.3, we define    as the nucleotide type for t
th
 group. For 
base    , {       }  and {       } respectively denote match or mismatch 
between    ’s nucleotide ty e    and the conditional nucleotide type   . Thus, we have 
  ( |  )  ∏  (  |  )
 
   
                                                                 
 ∏ ∏       
                  
     
  
    
 
   
                            
By pluging Eq. 3.4 into Eq. 3.3, the probability that    is the true base is  
  (  | )  
∏ ∏        
                  
       
    
 
   
∑ ∏ ∏        
                 
     
  
    
 
      {      }
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Where     is the base-calling error probability for base    , and can be obtained from 
Eq. 3.1.       is the cross-talk probability that is calculated from Eq. 3.2. With Eq. 3.5, 
we calculate the conditional probability for each nucleotide type. The one with maximal 
conditional probability is the nucleotide we detect at this position, and its corresponding 
probability is denoted with  . If the detected nucleotide is different from reference 
genome, we define it as a SNP. 
 
4. RESULTS 
4.1. Cross-talk study 
 Cross-talk is one of the major sources of error for Illumina sequencing. The 
Illumina Genome Analyzer uses two lasers and four filters to detect the nucleotides 
labeled with different dyes. Due to the overlap of the emission spectra of the four 
fluorophores, the detected images are not independent. The intensities of A and C are 
correlated as are those of G and T [66, 67]. Thus, the probabilities of miscalling for 
different nucleotide types should vary. 
 .  To control the quality and facilitate base calling, PhiX, a virus with a small 
and well-defined genome containing about 45% GC and 55% AT, is sequenced together 
with sequencing samples. Because of its properties, PhiX sequencing data is suitable for 
the cross-talk study. Firstly, we compared the cross-talk of PhiX data from 8 
independent runs. To evaluate the cross-talk, we divided the sequencing errors into 
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groups based on the nucleotide types of the true base and the miscalling base, and 
calculated the sequencing error rates for each group by  
     
                                   
                         
 
Where R is the nucleotide on the reference genome, and S is the aligned nucleotide from 
the sequencing reads. For example, for      the numerator is the number of Cs in the 
reads that are aligned to As in the reference genome, and the denominator is the total 
number mismatched bases in the reads. Because    , there are totally 12 types of      
and their summation should be 1. As shown in Figure 3.2, the cross-talk patterns for 
different runs are not consistent. For instance,      and      are very large for data 5, but 
very small for data 4. Secondly, we compared the cross-talk among different lanes in a 
single run. Since PhiX is sequenced for calibration purpose, usually it only takes one 
lane in a run. Thus, additionally to PhiX data, we used two lanes of reads sequenced 
from E.coli to study the cross-talk among different lanes. E.coli genome is relatively 
small and contains far fewer SNPs compared with Mammalian, so it is suitable for the 
sequencing error study. In Figure 3.3 (a), Lane 1 and Lane 2 are from E.coli 
sequencing reads, while Lane 8 is from PhiX sequencing reads in the same run. 
Obviously, these three lanes share the same cross-talk pattern. Lastly, we looked at the 
cross-talk for different tiles in the same lane. A lane of PhiX sequencing reads were 
divided into two groups: one composed of 1-49 tiles, and one composed of 50-100 tiles. 
We found that the sequencing patterns of these two groups are quite similar (Figure 3.3 
(b)). Therefore, the cross-talk patterns vary for different sequencing runs, but are 
consistent in each single run. 
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Figure 3.2. Cross-talk patterns for different runs are not consistent. Sequencing 
errors were classified for 8 sets of PhiX data from 8 independent sequencing runs. The 
vertical axis is the error type based on the nucleotide type. For example, "A,C" 
represents that the true nucleotide is A, but it is miscalled to C. The horizontal axis is 
the relative error rate, which is calculated by      
                                   
                         
. 
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Figure 3.3. Cross-talk patterns are consistent in a run. Sequencing errors were 
classified in the same way as Figure 3.2. (a) We compared the cross-talk patterns of 
different lanes from the same sequencing run. Lane 1 and Lane 2 were sequenced from 
E.coli genome. Lane 8 is sequenced from PhiX. (b) A single lane of PhiX sequencing 
data was divided into two groups based on tiles. The cross-talk patterns of these two 
groups are consistent.  
  
63 
 
4.1. Model testing with PhiX data 
 We tested our method with the PhiX data by manually mutating some positions 
on the PhiX genome, and using the mutated genome as the reference genome. Thus, the 
mutated positions serve as the gold standard of SNP sites. As shown in Figure 3.4, the 
coverage of the PhiX genome by the sequencing reads is high and uniform. The average 
sequencing depth is about 73. We applied our method to this dataset, and compared our 
results with the gold standard mutations (Figure 3.5). The SNPs called by our method 
exactly match the gold standard. All the SNPs were correctly called, and no false 
positive SNPs were observed. 
 
4.1. SNPs detection for prostate cancer cell line PC-3 
 Prostate cancer usually occurs in old men, and is the most common cause of 
death from cancer in men over age 75. PC-3 is a human prostatic carcinoma cell line, 
which is initiated from a bone metastasis of a grade IV prostatic adenocarcinoma from a 
62-year-old man [68, 69]. PC-3 is near-triploid with a modal number of 62 
chromosomes. PC-3 has a unique karyotype. Normal chromosomes N2, N3, N4, N5, 
N12, and N15 are absent. The mutation status of PC-3 is still unknown. The PC-3 data 
we obtained were originally generated for the epigenetic studies of histone modification 
with ChIP-Seq, so its coverage is low and uneven. Therefore, PC-3 dataset is perfect for 
testing the performance of our method on low coverage data. 
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Figure 3.4. Genome coverage of PhiX by the sequencing reads used for testing our 
method. The coverage is high and uniform. Average coverage is about 73, which is 
shown as the blue line. 
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Figure 3.5 Comparison of the gold standard mutations and the SNPs detected by 
our method. The cyan color represents the gold standard mutations we generated, and 
the orange color represents the SNPs we detected. The mutations we generated are 
identical to the mutations detected by our methods. 
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4.2.1. Coverage of PC-3 sequencing data 
 We aligned the reads of PC-3 dataset with Bowtie's v-mode by allowing up to 3 
mismatches for the whole read [56], and calculated the coverage for different regions in 
human genome with BEDTools [70]. There are many gaps in the reference human 
genome, which cannot be sequenced or mapped. The largest gaps exist in the highly 
repetitive regions of the genome - mostly around the centromeres and other 
heterochromatic regions. Some gaps also locate at gene clusters. To obtain an accurate 
coverage, we subtracted these gaps from the reference genome and used the gapless 
genome in the calculation. As shown in Table 3.1, ~50% of the genome is sequenced, 
and most of the sequencing reads aligned to the non-exonic regions. ~ 90% of the 
sequenced positions are covered with 4 or fewer reads, and only < 5% of the sequenced 
positions are covered with 6 or more reads (Figure 3.6). The average sequencing depths 
for different regions are less than 3, while the maximum sequencing depths are very 
large, indicating that the coverage is low and uneven. The average sequencing depth 
here is the average from the covered positions.  
 
4.2.1. Characterization of the identified SNPs for PC-3 
 To assess the specificity of our method, we compared the identified SNPs with 
dbSNP (Single Nucleotide Polymorphism Database) and 1000-genome database. 
dbSNP is a free public archive for genetic variation developed and hosted by NCBI. 
Until now, most variants have been catalogued by dbSNP. Since most genetic variants 
in one individual should have been previously observed from other people, usually  
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Table 3.1 Coverage of PC-3 dataset 
 
Sequencing depth Covered regions 
 
Maximum Average Number of bases (Mb) Percentage 
Whole-genome 12429 1.2 1419.7 49.60% 
Gene region 771 1.3 1276.3 52.70% 
Exome 771 2.6 83.2 66.30% 
CDS (coding sequence) 348 2.6 41.7 72.80% 
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Figure 3.6 The distribution of the sequencing depth of PC-3 dataset in the whole 
genome. (a) Density distribution: the proportion of covered positions at different 
sequencing depth. (b) Cumulative distribution: proportion of the positions covered at 
equal or less than specified depth. So the sequencing depth is very low, and about 95% 
of the sequenced genome is covered with 6 or fewer reads. Note that the proportion here 
is calculated with respect to the positions with at least one read aligned.  
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dbSNP is used as the standard to measure the specificity of SNP detection. dbSNP has 
been constantly updated, so >90% of the SNPs are expected to be discovered in dbSNP . 
Although the presence in dbSNP does not absolutely confirm the authenticity of the 
SNP, since the dbSNP build 135 contains 47.8 million SNPs (only 1.6% of the whole 
genome) , the relative difference between call sets should be able to reflect the quality 
differences. Similarly to dbSNP, 1000-genome database is also a large public variation 
data resource, which is established by sequencing the genomes of a large number of 
people. The current 1000-genome database contains 38 million SNPs (1.3% of the 
whole genome). In this article, we use dbSNP rate as the percentage of the SNPs 
discovered in dbSNP, and use 1000-genome rate as the proportion of the SNPs 
described in 1000-genome database. 
 The majority of the SNPs in PC-3 detected by our method are previously 
described by dbSNP and 1000-genome database, suggesting that our method works very 
well on PC-3 data. As shown in Figure 3.7(a) and Figure 3.8(a), the dbSNP rate and 
1000-genome rate increase when the cutoff of the SNP allele count increases. For the 
SNPs with allele counts equal or larger than 3, over 90% of the SNPs are discovered in 
the dbSNP or 1000-genome database.  Recall that  denotes the conditional probability 
of called SNP. With the increase of  value, the dbSNP rate and 1000-genome rate also 
increase (Figure 3.7(b) and Figure 3.8(b)).  
 To improve the SNP calls, we use the product of allele count and   to control 
the quality. SNPs with                 below the cutoff value will be removed from 
the final result. Setting the cutoff too large will miss a lot of true SNPs, while setting the 
cutoff too small will produce many false positive SNPs. Thus, varying the value of this  
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               (a) 
 
                 (b) 
 
Figure 3.7 Comparison of PC-3 SNPs detected with our method to dbSNP. With the 
increase of cutoff for (a) SNP allele count and (b)  value, dbSNP rate increases.  
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               (a)  
 
               (b) 
 
Figure 3.8 Comparison of PC-3 SNPs detected with our method to 1000-genome 
database. With the increase of cutoff for (a) SNP allele count and (b)  value, 1000-
genome rate increases.  
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Figure 3.9 Removing the Duplicates slightly increase the dbSNP rate. At various 
cutoff point of allele-count * , the dbSNP rates after removing the duplicates become 
higher. 
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cutoff value results in a trade-off between sensitivity and specificity. For PC-3 data, to 
balance the sensitivity and specificity, we set the cutoff value to 2, with which about 
94.4% of SNPs overlap with dbSNP (Figure 3.9).  
 Duplicate reads contribute to the false positive SNPs. When the sequencing 
library preparation involved the PCR amplification step, duplicated reads are usually 
observed. Duplicate reads from PCR amplification usually results in areas of high 
disproportional high coverage, and are often the cause of false positive in SNP calling, 
especially when the replication errors are made by the enzymes during the amplification. 
So we removed the duplicate reads that share common coordinates, sequencing 
direction and same sequence. The effect of removing duplicates varies in different 
datasets. For PC-3, removing the duplicates slightly improved the SNP calling, and the 
improvement becomes more significant when the cutoff value increases (Figure 3.9). It 
is reasonable because the PC-3 data is from many experiments and the majority of the 
PC-3 covered positions has low sequencing depth, indicating that the duplicate rate is 
low. The duplicate rate is larger for the positions with higher sequencing depth, so the 
effect of removing duplicates is more significant for higher depth. 
 
4.2.2. Comparison with other SNP detection tools 
 To evaluate the performance of our method, especially its ability of detecting 
SNPs from low coverage data, we compared our method with Varscan - a very popular 
variant-calling method, which has the adaptability to extreme read depth and pooled 
samples. It employs a robust heuristic/statistic approach to call variants. With optimized 
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setting for the parameters, Varscan called 115,571 SNPs, of which 101,736 are 
observed in dbSNP. Our method detected 526,925 SNPs and 497,526 of them are 
discovered in dbSNP (Table 3.2). So our method found about 4.5 times more SNPs 
than Varscan, while maintaining a higher dbSNP rate (94.42% versus 88.03%), 
indicating that our method is more sensitive and specific than Varscan for PC-3 data. 
 Transition/transversion ratio (Ti/Tv) is a critical metric to assess the specificity 
of SNP-calling. Transition is the substitution of a purine by a purine or a pyrimidine by 
a pyrimidine (       ). Transversion is a change from purine to pyrimidine, or 
vice versa (               ). Ti/Tv is 0.5 when there is no bias towards 
either transition or transversion, because the two kinds substitutions are equal probable, 
and there are twice as many transversions than transitions. However, for all the 
genomes examined so far, transitions occur more frequently than transversions [73-77]. 
Ti/Tv is known to be a general property of DNA sequence evolution. Inter-species 
comparison and previous sequencing projects showed that the Ti/Tv for the genome-
wide variants is ~2.0-2.1, and the exonic Ti/Tv is ~3.0-3.5 [78, 79]. Given the observed 
Ti/Tv, the false discovery rate (FDR) can be obtained by 
      
                 
                 
 
where the               is the expected value of Ti/Tv. We let               equal 
2.05 for whole genome and 3.25 for exome. As shown in Table 3.2,  Ti/Tv obtained by 
our method is 1.98, which is more close to the standard genome-wide Ti/Tv (2.0-2.1) 
than the Varscan Ti/Tv (1.68).  Also, the FDR of our method is only 0.04, which is 
<0.05 and much better than the Varscan FDR (0.24).  
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Table 3.2 Comparison of our method with Varscan for PC-3 data. In the calculation 
of FDR, 2.05 is used as the expected Ti/Tv ratio. 
 our method Varscan 
Number of called SNPs 526,925 115,571 
Number of SNPs observed in dbSNP 497,526 101,736 
dbSNP rate (%) 94.42 88.03 
Ti/Tv ratio 1.98 1.68 
FDR 0.04 0.24 
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4.2.3. Annotation of SNPs in PC-3 
 We annotated the SNPs with ANNOVAR - a tool for functionally annotating the 
genetic variants [80]. Based on the function of the DNA sequences where the SNPs 
aligned, SNPs are classified as intergenic SNPs, intronic SNPs, exonic SNPs, splicing 
site SNPs, upstream/downstream SNPs, 5' / 3' UTR (untranslated region) SNPs, and 
ncRNA (non-coding RNA) SNPs. Here, splicing site SNP is the SNP within 2-bp of a 
splicing junction, and upstream/downstream SNP is the SNP overlaps 1-kb region 
upstream/downstream of transcription start/end site. Consistent to the distribution of the 
sequencing reads of PC-3, most of the SNPs detected by our method are in intergenic 
and intronic regions (Figure 3.10 (a) ). We also found that the dbSNP rates of different 
regions vary (Figure 3.10 (b) ). The splicing site SNPs for both RNA and ncRNA have 
lower dbSNP rates than the other regions. The detailed numbers are listed in Table 3.3 
(a). Based on the effect of the substitution to the genetic coding, exonic SNPs are 
further grouped  into synonymous SNPs, nonsynonymous SNPs, stopgain SNPs, 
stoploss SNPs, and unknown SNPs (Table 3.3 (b) ). Stopgain SNPs are very important, 
because they result in truncated, incomplete, and usually nonfunctional protein product. 
There are four novel stopgain SNPs and one novel stoploss SNP discovered in PC-3 
data (Table S2 ). 
 To identify the potential causal genes responsible for the prostate cancer, we 
prioritized the SNPs in several steps (Figure 3.11). Although exons only constitute 
about 1% of the human genome [15], it is estimated that the protein coding regions 
constitute about 85% of the disease-causing variants [81]. There is also highly 
functional variation in the splicing sites [82], so we first perform a gene-based 
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(a) 
 
(b) 
 
Figure 3.10. (a) Pie chart of PC-3 SNPs for different genome regions. (b) 
Percentage of SNPs observed in dbSNP for different regions. 
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Table 3.3 Classification of PC-3 SNPs. 
(a) Classification of PC-3 SNPs by genome region. 
 Number of called 
SNPs 
Number of SNPs 
observed in dbSNP 
dbSNP rate 
(%) 
downstream 3,361 3,206 95.39 
exonic 6,243 5,839 93.53 
exonic; splicing 60 54 90.00 
intergenic 304,694 284,260 93.29 
intronic 184,877 177,945 96.25 
ncRNA_exonic 1,505 1,424 94.62 
ncRNA_intronic 13,178 12,542 95.17 
ncRNA_splicing 7 6 85.71 
ncRNA_UTR3 66 63 95.45 
ncRNA_UTR5 30 30 100.00 
splicing 49 36 73.47 
upstream 6,305 5,961 94.54 
upstream; downstream 199 183 91.96 
UTR3 3,948 3,780 95.74 
UTR5 2,400 2,194 91.42 
UTR5;UTR3 3 3 100.00 
 
(b) Classification of exonic SNPs of PC-3 by genetic coding. 
 Number of called SNPs Number of SNPs observed in dbSNP 
nonsynonymous 2,991 2,735 
synonymous 3,169 3,029 
stopgain 25 21 
stoploss 3 2 
unknown 115 106 
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Figure 3.11. Prioritization of causal genes for PC-3. 
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annotation to identify 526,925 SNPs locating at exons or splicing sites. We then filtered 
the SNPs from 1000-genome database, ESP (NHLBI GO Exome Sequencing Project) 
6500 database, dbSNP135 database and CG (Complete Genomics) 69 database, 
assuming that the SNPs observed in public databases are less likely to be causal SNPs 
of cancer. ESP is to discover novel genes and mechanism contributing to the lung, heart 
and blood disorder, and its database is constituted of the variants sequenced from 6500 
exomes of the human genome across diverse, richly-phenotyped populations. CG69 is 
the variant database established by Complete Genomics Company by sequencing 69 
whole human genomes. The novel SNPs were then scored by SIFT [83] and PolyPhen 
[84] - tools to predicts the importance of variants to the protein function. Generally, 
SN s with SIFT score ≤ 0.05 or  oly hen score ≥ 0.85 are  redicted to be deleterious. 
Totally, 131 SNPs passed all the filters and 107 genes were identified as the causal 
genes, of which the detail information  is listed in Table S3. 
 
4.2. SNPs detection for colon cancer cell lines RKO and SW48 
 American Cancer Society reported that colon cancer is one of the leading causes 
of cancer-related deaths in the United States. However, colon cancer can often be 
completely cured with early diagnosis. Identification of the causal variants for colon 
cancer may greatly contribute to the early diagnosis, and therefore can be particularly 
significant. RKO and SW48 are two colon cancer cell lines that are used as in vitro 
models for colorectal cancer to study biochemical mechanisms of carcinoma formation. 
However, the mutation statuses of RKO and SW48 remain unknown. On the other hand, 
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exome sequencing is the most popular sequencing strategy for the variants detection. 
Compared with the whole genome sequencing, exome sequencing is cheaper but still 
effective, because exome is usually more straightforwardly related to the diseases. 
Different from whole genome sequencing, exome sequencing data usually has higher 
coverage and contains more duplicates. Here, we applied our method to detect the SNPs 
in RKO and SW48 cell lines, not only showing the performance of our method on the 
exome sequencing data, but also providing valuable information for the future colon 
cancer study. 
 
4.3.1. Coverage of RKO and SW48 sequencing data 
 RKO and SW48 are sequenced by exome capture and RNA-seq, so most of the 
reads align to the exome. The coverage of PKO and SW48 data are similar (Table 3.4), 
because same protocols were applied in the experiments. ~ 60% of exome and ~ 80% of 
CDS region are sequenced, with the average sequencing depths of ~65 for exome and 
~35 for CDS. Compared with PC-3 data, the sequencing depths of RKO and SW48 are 
much higher and more evenly distributed. ~95% of the sequenced positions are covered 
by 1-200 reads (Figure 3.12). 
 
4.3.1. Characterization of the identified SNPs for RKO and SW48 
 Similar to PC-3 data, the dbSNP rates and 1000-genome rates of RKO and 
SW48 also positively relate to the SNP allele count and  value. With an appropriate  
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Table 3.4 Coverage of RKO and SW48 dataset. 
 sequencing depth covered regions 
maximum average number of bases (Mb) percentage 
RKO 
Exome 293,247 35.5 76.2 60.67% 
CDS 63,609 64.7 47.2 82.36% 
SW48 
Exome 329,032 34.7 79.2 63.12% 
CDS 86,703 63.2 48.1 83.96% 
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Figure 3.12 The distribution of the sequencing depth of RKO and SW48 datasets 
in the CDS region. (a) Density distribution: proportion of the covered positions at 
different sequencing depths. (b) Cumulative distribution: proportion of the positions 
covered at equal or less than specified depth. Therefore, majority of the sequencing 
depths almost uniformly distributed in from 1-100, and ~95% of the CDS region has ≤ 
reads aligned. Note that the proportion here is calculated with respect to the positions in 
CDS that are covered with at least one read. 
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cutoff for the product of SNP allele count and  value, we identified 95,142 SNPs for 
RKO, of which 76,836 are discovered in dbSNP. Similarly, 101,088 SNPs are detected 
from SW48 dataset, and 76,560 of them are overlapped with dbSNP. The dbSNP rates 
are 80.76% and 80.90% respectively. 
 The effect of the duplicate reads was measured. After the duplicate reads are 
removed, the dbSNP rates show a trend to increase (Figure 3.13).  Compared with PC-3, 
the increases for RKO and SW48 are more significant. PC-3 dataset is from many 
experiments with low sequencing depth, so the duplicate rate is low. RKO and SW48 
datasets contain exome sequencing reads which usually have high duplicate rate.  
Therefore, removing duplicates could highly improve the SNP calling quality for RKO 
and SW48 datasets.  
 
4.3.2. Comparison with other SNP detection tools  
 To evaluate the performance of our method on exome capture data, we also ran 
the RKO and SW48 dataset with Varscan and DNAnexus. DNAnexus is a commercial 
software for NGS analysis including variation detection. For RKO, Varscan detects 
101,088 SNPs with 76,560 overlapped with dbSNP (Table 3.5). Compared with 
Varscan, our method detects ~300 more possibly right variants (variants described in 
dbSNP) and obtains higher dbSNP rate (80.76% versus 75.74%). Our method  also 
outperforms DNAnexus on SNPs detection. DNAnexus detects much fewer SNPs in 
dbSNP (52,923), and the dbSNP rate (59.57%) is much lower than our method 
(80.76%). The Ti/Tv ratios of Varscan and our method are higher than that of  
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Figure 3.13 Removing the Duplicates increase the dbSNP rate significantly. At 
various cutoff point of allele-count * , the dbSNP rates after removing the duplicates 
become higher. 
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Table 3.5 Comparison of different tools for calling SNPs in RKO and SW48 cell 
lines.  
  our method Varscan DNAnexus 
RKO total SNP 95,142 101,088 88,849 
SNPs in dbSNP 76,836 76,560 52,923 
dbSNP rate (%) 80.76 75.74 59.57 
Ti/Tv ratio 2.15 2.22 1.38 
FDR  
(              = 2.34) 
0.10 0.07 0.52 
SW48 total SNP 113,195 121,494 94,958 
SNPs in dbSNP 92,706 86,014 56,862 
dbSNP rate (%) 81.90 70.80 59.88 
Ti/Tv ratio 2.13 2.07 1.42 
FDR 
(              = 2.3) 
0.09 0.13 0.49 
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DNAnexus, which is consistent to the dbSNP rates. Note that even the Ti/Tv ratios 
calculated by Varscan and our method are only ~ 2.2, which is far smaller than the 
expected Ti/Tv ratio for exome (3.0-3.5). This is because that in the RKO and SW48 
datasets a lot of reads are from non-exonic region, reducing the Ti/Tv ratio. The Ti/Tv 
ratio for the SNPs described in dbSNP is ~2.3, proving that the low Ti/Tv ratio is not 
caused by inaccurate call. Since ~ 75% of the SNPs are from intronic and intergenic 
region, we modify                to 2.34 according the percentage of exonic SNPs in 
total SNPs. The FDRs calculated with the modified                are consistent with 
the dbSNP rates. Similar results are obtained for SW48. 
 
4.3.3. Annotation and comparison of SNPs in RKO and SW48 
 We compared the SNPs of RKO and SW48, and found 32,224 SNPs in common, 
which is 33.87% and 28.47% of SNPs in RKO and SW48 respectively. Among these 
common SNPs, 28,326 (87.90%) SNPs are found in dbSNP (Table 3.6). With the same 
method we applied to PC-3, we annotate the SNPs in RKO and SW48 and classified 
them by their functions, then we found that SNPs from these two datasets distribute in a 
very similar pattern (Figure 3.14 (a) ), which is possibly because these two datasets 
share the same experiment protocol. ~ 50%-60% SNPs are intronic and 20% SNPs are 
intergenic, which explained the low Ti/Tv ratios. Only about 15% SNPs are from 
exome. The dbSNP rate varies for the SNPs with different functions (Figure 3.14 (b)). 
Similar to PC-3 data, the dbSNP rate for splicing SNPs are much lower than the others. 
Exonic SNPs are grouped by their effect to genetic coding (Table 3.7). 47 stopgain  
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Table 3.6 Classification of RKO and SW48 SNPs and their common SNPs. 
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Figure 3.14 (a) Pie charts of RKO and SW48 SNPs for different genome regions. 
 
 
 
downstream
exonic
exonic;splicing
intergenic
intronic
ncRNA_exonic
ncRNA_intronic
ncRNA_splicing
ncRNA_UTR3
ncRNA_UTR5
splicing
upstream
upstream;downstream
UTR3
UTR5
UTR5;UTR3
downstream
exonic
exonic;splicing
intergenic
intronic
ncRNA_exonic
ncRNA_intronic
ncRNA_splicing
ncRNA_UTR3
ncRNA_UTR5
splicing
upstream
upstream;downstream
UTR3
UTR5
SW48 
RKO 
90 
 
 
 
Figure 3.14 (b) Percentage of RKO and SW48 SNPs observed in dbSNP for 
different regions. 
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Table 3.7 Classification of exonic SNPs in RKO and SW48 by genetic coding. 
 RKO SW48 common 
 total in dbSNP total in dbSNP total in dbSNP 
nonsynonymous 5,563 4,781 4,814 4,195 2,230 2,201 
synonymous 6,070 5,738 5,393 5,141 2,566 2,552 
stopgain 47 24 54 27 12 12 
stoploss 8 8 9 7 2 2 
unknown 54 48 65 55 26 24 
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SNPs are found for RKO, and 54 stopgain SNPs are found for SW48. Among these 
stopgain SNPs, 12 SNPs are in common. Novel stopgain and stoploss SNPs that are not 
discovered in dbSNP are listed in Table S4.  
 To identify the potential causal genes for RKO and SW48, we applied the same 
method used for PC-3 to prioritize the SNPs (Figure 3.15). The exonic/splicing 
nonsynonymous SNPs are filtered with 1000-genome database, ESP6500 database, 
dbSNP135 database and CG69 database. Furthermore, the SNPs that are believed to be 
benign by SIFT and PolyPhen are removed. For RKO and SW48, we found 1188 and 
1213 SNPs respectively, which correspond to 701 and 652 genes. 292 genes are in 
common for RKO and SW48. 
 
5. DISCUSSION 
 The high throughput of NGS provides the possibility to completely study the 
genome-wide variation, but it also challenges the algorithms for variants detection due 
to its high sequencing error rates. Most SNP calling methods work well for the high-
coverage data, so exome sequencing is the most common strategy for the variants study. 
Exome is the major disease-causing region but only constitutes about 1% of the human 
genome, so exome can be sequenced deeply without extra cost. However, exome 
sequencing is only able to detect the variants in the coding region of genes which 
control the protein function. It is unable to detect the variants from the remained 99% of 
the human genome, which can affect the gene regulatory and are also associated with 
diseases. But sequencing the whole genome deeply is not practical right now due to the  
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Figure 3.15. Prioritization of causal genes for RKO and SW48. 
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high cost. Therefore, we report a novel SNP calling algorithm which can achieve high 
sensitivity and specificity for low coverage data. We have showed that our method 
perform well on both low coverage ChIP-Seq data and high coverage Exome 
sequencing data. There are thousands of ChIP-Seq data, RNA-Seq data and some other 
sequencing data with low or uneven coverage conducted every year, which can also be 
used for the SNP detection with our method. We expect that by utilizing these data, the 
catalogue of the human genetic variants will grow fast. 
 A few verified SNPs have been reported for RKO and SW48. RKO has two 
verified substitutions: c.1799T>A in BRAF gene and c.3140A>G PIK3CA gene. The 
first one is shown in our result, but the second was not called because it is the allele 
with lower frequency and our method only report the primary allele. SW48 also has two 
verified substitutions: c.98C>A in CTNNB1 gene and c.2155G>A in EGFR gene. 
Similar to RKO, the first one was identified by our method, but the second one was not 
called because of its low frequency. The comparison between the verified SNPs and our 
results shows the reliability of our method. In this article, we only showed the SNPs that 
are the primary alleles, but our method can also be used to call the alternative allele by 
reporting the allele with second higher probability. Furthermore, our method is also able 
to call genotype using the ratio of the highest and second highest probability.  
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CHAPTER FOUR 
 
Conclusion 
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 In this article, we first present an algorithm that is highly robust and efficient at 
correcting errors in the NGS data. We demonstrated the effectiveness of MTM on both 
single-cell data with highly non-uniform coverage and normal data with uniformly high 
coverage, reflecting that MTM does not rely on the coverage of the sequencing reads. 
Compared with the previous tools Hammer and Quake, which beat the other tools on 
non-uniform and uniform data respectively, MTM showed better performance than 
Hammer and better or similar performance than Quake in terms of the positive 
predictive value and sensitivity. We also showed the benefits of error correction with 
MTM on the downstream analysis, such as mapping and SNP detection. 
 We then present a Bayesian-based approach for SNP calling, which improved 
the existing methods by having no limitation on the sequencing depth. We successfully 
applied this approach to identify the SNPs in prostate cancer cell line PC-3 and colon 
cancer cell lines RKO and SW48, whose mutation status are unknown. Our method 
outperforms the existing methods - Varscan and DNAnexus - by identifying more SNPs 
while maintaining higher dbSNP rates, especially for the low coverage PC-3 data. In 
summary, we identified 107 potential causal genes for PC-3. For RKO and SW48 cell 
lines, 701 and 652 potential causal genes were identified respectively, and 297 genes 
are in common. With the ability of piggybacking on the ChIP-Seq, mRNA-Seq and 
other sequencing data with low or uneven coverage, this approach is expected to have a 
wide range of applications. 
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Table S1. Data source of PC3 used in SNPs identification. 
Data ID Lane # Cell line Experiment 
090218_HWUSI-EAS182R_0001_30KPG 
1 PC3 LMN 
2 PC3 Pol2 
3 PC3 H3K4me3 
4 PC3 H3K9me2 
5 PC3 H3K27me3 
6 PC3 AGO2 
7 PC3 Total_H3 
090220_HWUSI-EAS182R_0002_30KR3 
1 PC3 LMN 
2 PC3 Pol2 
3 PC3 H3K4me3 
4 PC3 H3K9me2 
5 PC3 H3K27me3 
6 PC3 AGO2 
7 PC3 H3 
090512_HWUSI-EAS230-R_0003_30NYJ 
1 PC3 LMN 
2 PC3 Pol2 
3 PC3 H3K4me3 
4 PC3 H3K9me2 
5 PC3 H3K27me3 
6 PC3 AGO2 
7 PC3 Total_H3 
090526_HWUSI-EAS230-R_0006_30P04 
1 PC3 H3K9me2 
2 PC3 H3K9me2 
3 PC3 H3K9me2 
4 PC3 H3K9me3 
5 PC3 H3K9me3 
6 PC3 H3K9me3 
090327_HWUSI-EAS182R_0006_30M3H 
3 PC3 input 
4 PC3 H3 
5 PC3 H3K4me3 
6 PC3 H3K27me3 
7 PC3 input 
090327_HWUSI-EAS182R_0006_30MKR 
1 PC3 input 
2 PC3 H3 
3 PC3 H3K4me3 
4 PC3 H3K27me3 
5 PC3 input 
090526_HWUSI-EAS230-R_0006_30P04 7 PC3 H3K27me3 
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090507_HWUSI-EAS230-R_0002_30NWT 
6 PC3 H3 
7 PC3 H3K4me3 
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Table S2. Noval stopgain and stoploss SNPs for PC-3 
function chromosome position ref SNP Gene information 
stopgain chr3 160155983 A T 
TRIM59:NM_173084:exon3:c.
T989A:p.L330X, 
stopgain chr12 56647988 C A 
ANKRD52:NM_173595:exon8
:c.G769T:p.E257X, 
stopgain chr16 1822802 G A 
MRPS34:NM_023936:exon1:c
.C319T:p.Q107X, 
stopgain chr19 50916763 C A 
POLD1:NM_001256849:exon1
8:c.C2235A:p.Y745X,POLD1:
NM_002691:exon18:c.C2235A
:p.Y745X, 
stoploss chr19 35633644 T G 
FXYD1:NM_005031:exon7:c.
T277G:p.X93E,FXYD1:NM_0
21902:exon7:c.T277G:p.X93E, 
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Table S3. Potential causal genes identified by our method for PC-3 
Gene 
Symbol 
SNPs 
number 
Entrez Gene Name Location Type(s) 
CTBP2 3 C-terminal binding protein 2 Nucleus transcription 
regulator 
ZNF717 2 zinc finger protein 717 Nucleus other 
NOXO1 2 NADPH oxidase organizer 1 Plasma 
Membrane 
other 
ALG9 2 asparagine-linked glycosylation 9, alpha-
1,2-mannosyltransferase homolog (S. 
cerevisiae) 
Cytoplasm enzyme 
KIR2DL3 2 killer cell immunoglobulin-like receptor, 
two domains, long cytoplasmic tail, 3 
Plasma 
Membrane 
other 
RARRES2 2 retinoic acid receptor responder 
(tazarotene induced) 2 
Plasma 
Membrane 
transmembrane 
receptor 
CHD8 2 chromodomain helicase DNA binding 
protein 8 
Nucleus enzyme 
SNX18 2 sorting nexin 18 Cytoplasm transporter 
UNC80 2 unc-80 homolog (C. elegans) unknown other 
CCDC57 2 coiled-coil domain containing 57 unknown other 
DUSP28 2 dual specificity phosphatase 28 unknown enzyme 
PTPRM 2 protein tyrosine phosphatase, receptor 
type, M 
Plasma 
Membrane 
phosphatase 
LLGL1 2 lethal giant larvae homolog 1 
(Drosophila) 
Cytoplasm other 
FAM174B 2 family with sequence similarity 174, 
member B 
unknown other 
VEPH1 1 ventricular zone expressed PH domain 
homolog 1 (zebrafish) 
Nucleus other 
MMS19 1 MMS19 nucleotide excision repair 
homolog (S. cerevisiae) 
Nucleus transcription 
regulator 
FREM3 1 FRAS1 related extracellular matrix 3 Extracellular 
Space 
other 
IFI35 1 interferon-induced protein 35 Nucleus other 
PLD4 1 phospholipase D family, member 4 Extracellular 
Space 
enzyme 
URB1 1 URB1 ribosome biogenesis 1 homolog 
(S. cerevisiae) 
Nucleus other 
GATA2 1 GATA binding protein 2 Nucleus transcription 
regulator 
DAPP1 1 dual adaptor of phosphotyrosine and 3-
phosphoinositides 
Cytoplasm other 
DSE 1 dermatan sulfate epimerase Cytoplasm enzyme 
RUNX3 1 runt-related transcription factor 3 Nucleus transcription 
regulator 
EYS 1 eyes shut homolog (Drosophila) unknown other 
THAP3 1 THAP domain containing, apoptosis 
associated protein 3 
unknown other 
RBMXL3 1 RNA binding motif protein, X-linked-like 
3 
unknown other 
NTN3 1 netrin 3 Extracellular 
Space 
other 
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FEM1A 1 fem-1 homolog a (C. elegans) Nucleus transcription 
regulator 
RAP2A 1 RAP2A, member of RAS oncogene 
family 
Plasma 
Membrane 
enzyme 
DMRT1 1 doublesex and mab-3 related transcription 
factor 1 
Nucleus transcription 
regulator 
TMC2 1 transmembrane channel-like 2 Plasma 
Membrane 
other 
OBSCN 1 obscurin, cytoskeletal calmodulin and 
titin-interacting RhoGEF 
Cytoplasm kinase 
EIF4G2 1 eukaryotic translation initiation factor 4 
gamma, 2 
Cytoplasm translation 
regulator 
AEN 1 apoptosis enhancing nuclease Nucleus enzyme 
GFM2 1 G elongation factor, mitochondrial 2 Cytoplasm translation 
regulator 
COPB2 1 coatomer protein complex, subunit beta 2 
(beta prime) 
Cytoplasm transporter 
OR4D9 1 olfactory receptor, family 4, subfamily D, 
member 9 
Plasma 
Membrane 
G-protein 
coupled 
receptor 
KIF5C 1 kinesin family member 5C Cytoplasm other 
CDC27 1 cell division cycle 27 homolog (S. 
cerevisiae) 
Nucleus other 
SGPP2 1 sphingosine-1-phosphate phosphatase 2 Cytoplasm phosphatase 
CTBP1 1 C-terminal binding protein 1 Nucleus enzyme 
CUL9 1 cullin 9 Cytoplasm other 
UTP18 1 UTP18 small subunit (SSU) processome 
component homolog (yeast) 
Nucleus other 
C17orf100 1 chromosome 17 open reading frame 100 unknown other 
DUSP5 1 dual specificity phosphatase 5 Nucleus phosphatase 
EPPK1 1 epiplakin 1 Cytoplasm other 
RHPN1 1 rhophilin, Rho GTPase binding protein 1 Cytoplasm other 
MLL3 1 myeloid/lymphoid or mixed-lineage 
leukemia 3 
Nucleus transcription 
regulator 
AP2A1 1 adaptor-related protein complex 2, alpha 
1 subunit 
Cytoplasm transporter 
LRRIQ1 1 leucine-rich repeats and IQ motif 
containing 1 
unknown other 
CATSPER
1 
1 cation channel, sperm associated 1 Plasma 
Membrane 
ion channel 
PRSS56 1 protease, serine, 56 unknown other 
ODZ2 1 odz, odd Oz/ten-m homolog 2 
(Drosophila) 
Plasma 
Membrane 
other 
MYH2 1 myosin, heavy chain 2, skeletal muscle, 
adult 
Cytoplasm enzyme 
SNED1 1 sushi, nidogen and EGF-like domains 1 Plasma 
Membrane 
other 
G6PD 1 glucose-6-phosphate dehydrogenase Cytoplasm enzyme 
ONECUT
3 
1 one cut homeobox 3 Nucleus transcription 
regulator 
KLC1 1 kinesin light chain 1 Cytoplasm other 
NLK 1 nemo-like kinase Nucleus kinase 
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MUC2 1 mucin 2, oligomeric mucus/gel-forming unknown other 
C11orf9 1 chromosome 11 open reading frame 9 Nucleus transcription 
regulator 
C17orf105 1 chromosome 17 open reading frame 105 unknown other 
SERINC4 1 serine incorporator 4 unknown other 
PPP4C 1 protein phosphatase 4, catalytic subunit Cytoplasm phosphatase 
C1orf172 1 chromosome 1 open reading frame 172 unknown other 
ABCA6 1 ATP-binding cassette, sub-family A 
(ABC1), member 6 
Plasma 
Membrane 
transporter 
FBLN2 1 fibulin 2 Extracellular 
Space 
other 
CLDN3 1 claudin 3 Plasma 
Membrane 
transmembrane 
receptor 
ERCC3 1 excision repair cross-complementing 
rodent repair deficiency, 
complementation group 3 
Nucleus enzyme 
TTLL3 1 tubulin tyrosine ligase-like family, 
member 3 
Extracellular 
Space 
enzyme 
KCNH2 1 potassium voltage-gated channel, 
subfamily H (eag-related), member 2 
Plasma 
Membrane 
ion channel 
MVP 1 major vault protein Nucleus other 
MUC6 1 mucin 6, oligomeric mucus/gel-forming Extracellular 
Space 
other 
FAM179A 1 family with sequence similarity 179, 
member A 
unknown other 
GRID1 1 glutamate receptor, ionotropic, delta 1 Plasma 
Membrane 
ion channel 
LHX3 1 LIM homeobox 3 Nucleus transcription 
regulator 
VWF 1 von Willebrand factor Extracellular 
Space 
other 
CTDSP2 1 CTD (carboxy-terminal domain, RNA 
polymerase II, polypeptide A) small 
phosphatase 2 
Nucleus phosphatase 
HK3 1 hexokinase 3 (white cell) Cytoplasm kinase 
PELP1 1 proline, glutamate and leucine rich 
protein 1 
Nucleus other 
PREX2 1 phosphatidylinositol-3,4,5-trisphosphate-
dependent Rac exchange factor 2 
Cytoplasm other 
ISYNA1 1 inositol-3-phosphate synthase 1 unknown enzyme 
KCNG2 1 potassium voltage-gated channel, 
subfamily G, member 2 
Plasma 
Membrane 
ion channel 
PCNXL2 1 pecanex-like 2 (Drosophila) unknown other 
HOXD10 1 homeobox D10 Nucleus transcription 
regulator 
DUX4 1 double homeobox 4 Nucleus transcription 
regulator 
FSCN1 1 fascin homolog 1, actin-bundling protein 
(Strongylocentrotus purpuratus) 
Cytoplasm other 
ELFN1 1 extracellular leucine-rich repeat and 
fibronectin type III domain containing 1 
unknown other 
ZNF649 1 zinc finger protein 649 Nucleus other 
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RYR1 1 ryanodine receptor 1 (skeletal) Cytoplasm ion channel 
TMEM59
L 
1 transmembrane protein 59-like Cytoplasm other 
ABCF3 1 ATP-binding cassette, sub-family F 
(GCN20), member 3 
unknown transporter 
MUC16 1 mucin 16, cell surface associated unknown other 
PPM1N 1 protein phosphatase, Mg2+/Mn2+ 
dependent, 1N (putative) 
Extracellular 
Space 
other 
C7 1 complement component 7 Extracellular 
Space 
other 
ANKRD52 1 ankyrin repeat domain 52 Nucleus transcription 
regulator 
FOXA1 1 forkhead box A1 Nucleus transcription 
regulator 
WDR34 1 WD repeat domain 34 Cytoplasm other 
FAM59B 1 family with sequence similarity 59, 
member B 
unknown other 
TPST2 1 tyrosylprotein sulfotransferase 2 Cytoplasm enzyme 
ISLR2 1 immunoglobulin superfamily containing 
leucine-rich repeat 2 
Plasma 
Membrane 
other 
FAT1 1 FAT tumor suppressor homolog 1 
(Drosophila) 
Plasma 
Membrane 
other 
SAMD11 1 sterile alpha motif domain containing 11 Nucleus other 
SSPO 1 SCO-spondin homolog (Bos taurus) Cytoplasm other 
KRTAP7 1 unkonwn unknown unknown 
HLA 1 unkonwn unknown unknown 
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Table S4. Noval stopgain and stoploss SNPs in RKO and SW48 
(a) Noval stopgain and stoploss SNPs in RKO 
function chromosome position reference SNP Gene information 
stopgain chr1 152185725 G A HRNR:NM_001009931:exon3:c.
C8380T:p.Q2794X, 
stopgain chr2 85255047 C T KCMF1:NM_020122:exon2:c.C5
2T:p.R18X, 
stopgain chr2 220160985 C T PTPRN:NM_001199764:exon18:
c.G2201A:p.W734X,PTPRN:NM
_001199763:exon17:c.G2384A:p
.W795X,PTPRN:NM_002846:ex
on18:c.G2471A:p.W824X, 
stopgain chr3 40211492 G T MYRIP:NM_015460:exon8:c.G7
81T:p.G261X, 
stopgain chr3 98109948 G T OR5K3:NM_001005516:exon1:c
.G439T:p.G147X, 
stopgain chr4 56225592 G T SRD5A3:NM_024592:exon2:c.G
301T:p.G101X, 
stopgain chr5 16671018 G A MYO10:NM_012334:exon39:c.C
5500T:p.R1834X, 
stopgain chr5 140579957 G T PCDHB11:NM_018931:exon1:c.
G610T:p.E204X, 
stopgain chr6 52696720 G A GSTA5:NM_153699:exon7:c.C5
95T:p.Q199X, 
stopgain chr6 152457756 G T SYNE1:NM_033071:exon141:c.
C25512A:p.C8504X,SYNE1:NM
_182961:exon141:c.C25656A:p.
C8552X, 
stopgain chr10 5773040 C T FAM208B:NM_017782:exon11:
c.C1078T:p.Q360X, 
stopgain chr12 85279758 G A SLC6A15:NM_018057:exon3:c.
C379T:p.R127X,SLC6A15:NM_
182767:exon3:c.C379T:p.R127X
,SLC6A15:NM_001146335:exon
2:c.C58T:p.R20X, 
stopgain chr12 112330854 G T MAPKAPK5:NM_139078:exon1
4:c.G1411T:p.E471X,MAPKAP
K5:NM_003668:exon14:c.G1405
T:p.E469X, 
stopgain chr13 47361163 C T ESD:NM_001984:exon4:c.G150
A:p.W50X, 
stopgain chr14 73491163 G T ZFYVE1:NM_021260:exon2:c.C
54A:p.C18X, 
stopgain chr16 50745326 C T NOD2:NM_022162:exon4:c.C15
04T:p.Q502X, 
stopgain chr17 7186639 C T SLC2A4:NM_001042:exon2:c.C
109T:p.Q37X, 
stopgain chr17 27049838 A T RPL23A:NM_000984:exon3:c.A
307T:p.K103X, 
stopgain chr17 62856696 C A LRRC37A3:NM_199340:exon11
:c.G3568T:p.E1190X, 
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stopgain chr17 78172484 C T CARD14:NM_052819:exon10:c.
C1234T:p.R412X, 
stopgain chr19 45575836 G A ZNF296:NM_145288:exon3:c.C
451T:p.R151X, 
stopgain chr20 10279932 C T SNAP25:NM_130811:exon7:c.C
424T:p.R142X,SNAP25:NM_00
3081:exon7:c.C424T:p.R142X, 
stopgain chr22 31331037 G A MORC2:NM_014941:exon20:c.
C1738T:p.R580X, 
 
(a) Noval stopgain and stoploss SNPs in SW48 
function chromosome position reference SNP Gene information 
stopgain chr1 15888764 C T DNAJC16:NM_015291:exon9:
c.C1282T:p.Q428X, 
stopgain chr1 85561701 C T WDR63:NM_145172:exon11:c
.C1261T:p.Q421X, 
stopgain chr1 108742652 C A SLC25A24:NM_013386:exon1
:c.G109T:p.G37X, 
stopgain chr1 151751716 T A TDRKH:NM_006862:exon5:c.
A424T:p.R142X,TDRKH:NM_
001083963:exon5:c.A424T:p.R
142X,TDRKH:NM_001083965
:exon5:c.A424T:p.R142X, 
stopgain chr1 157516869 C T FCRL5:NM_031281:exon3:c.G
171A:p.W57X,FCRL5:NM_00
1195388:exon3:c.G171A:p.W5
7X, 
stopgain chr2 54885067 C T SPTBN1:NM_178313:exon29:
c.C6088T:p.R2030X,SPTBN1:
NM_003128:exon30:c.C6127T:
p.R2043X, 
stopgain chr2 149543893 A T EPC2:NM_015630:exon14:c.A
2371T:p.R791X, 
stopgain chr2 198949979 C T PLCL1:NM_006226:exon2:c.C
1738T:p.R580X, 
stopgain chr2 236945333 C T AGAP1:NM_001037131:exon1
4:c.C1774T:p.Q592X,AGAP1:
NM_014914:exon13:c.C1615T:
p.Q539X, 
stopgain chr3 98304503 C T CPOX:NM_000097:exon5:c.G
954A:p.W318X, 
stopgain chr3 113374426 C A KIAA2018:NM_001009899:ex
on7:c.G6103T:p.G2035X, 
stopgain chr5 36036015 G A UGT3A2:NM_001168316:exo
n6:c.C1255T:p.Q419X,UGT3A
2:NM_174914:exon7:c.C1357T
:p.Q453X, 
stopgain chr5 98129453 T A RGMB:NM_001012761:exon5:
c.T1433A:p.L478X, 
stopgain chr5 112901596 C T YTHDC2:NM_022828:exon21:
c.C2722T:p.Q908X, 
stopgain chr6 152476161 G A SYNE1:NM_033071:exon132:
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c.C23782T:p.R7928X,SYNE1:
NM_182961:exon133:c.C2399
5T:p.R7999X, 
stopgain chr9 135601233 G A AK8:NM_152572:exon13:c.C1
282T:p.Q428X, 
stopgain chr11 124765398 G A ROBO4:NM_019055:exon6:c.
C991T:p.R331X, 
stopgain chr12 56295916 C A WIBG:NM_001143853:exon3:
c.G352T:p.E118X,WIBG:NM_
032345:exon3:c.G355T:p.E119
X, 
stopgain chr15 45003808 C T B2M:NM_004048:exon1:c.C64
T:p.Q22X, 
stopgain chr15 89862496 G A POLG:NM_001126131:exon19
:c.C3067T:p.Q1023X,POLG:N
M_002693:exon19:c.C3067T:p
.Q1023X, 
stopgain chr16 30581722 C A ZNF688:NM_145271:exon3:c.
G346T:p.E116X,ZNF688:NM_
001024683:exon3:c.G304T:p.E
102X, 
stopgain chr17 7673613 C T DNAH2:NM_020877:exon24:c
.C3985T:p.Q1329X, 
stopgain chr19 34941217 G A UBA2:NM_005499:exon9:c.G
819A:p.W273X, 
stopgain chr19 39219995 C T ACTN4:NM_004924:exon21:c.
C2659T:p.Q887X, 
stopgain chr19 49949888 G A PIH1D1:NM_017916:exon8:c.
C751T:p.Q251X, 
stopgain chrX 100417941 C A CENPI:NM_006733:exon21:c.
C2256A:p.C752X, 
stopgain chrX 117762191 G T DOCK11:NM_144658:exon34:
c.G3730T:p.E1244X, 
stoploss chr1 203137787 T C MYBPH:NM_004997:exon10:
c.A1434G:p.X478W, 
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